HealthHealth meansthe meansthe worldworld tous. tous.

66.320

23.50

0 0

23.50

66.320

baker heart research institute annual report 2004 MISSION Cardiovascular disease is the leading cause of death and disability worldwide and is responsible for over 40% of deaths in Australia each year.The risk factors for cardiovascular disease are highly prevalent in the Australian community with 80% of all adults having one of the following risk factors: Smoking Inactivity High blood pressure Obesity Diabetes Depression Social isolation High Cholesterol

At the Baker, our mission is to reduce death and disability from cardiovascular disease.We achieve this through activities ranging from research at the laboratory bench to clinical trials, patient care and education.

The major areas of research at the Baker are: • The risk factors and prevention of heart disease and stroke • Coronary disease, heart attack and sudden coronary death • Heart failure • Diabetes and its complications

The Baker Heart Research Institute is funded from a diverse range of government and private sources.We remain grateful for the continuing support of the corporate sector, trusts, foundations and individual donations.

2 CONTENTS

ABOUT THE BAKER 4

A WORD FROM OUR PATRON 4

PRESIDENT’S REPORT 5

DIRECTOR’S REPORT 8

ORGANISATION STRUCTURE 11

INTERNATIONAL SCIENTISTS 12

SCIENTIFIC OVERVIEW

HEART - Cardiology Division 14 BRAIN - Cardiovascular Neuroscience Division 15 VESSELS - Vascular Division 17

CORE FACILITIES 19

GRADUATING STUDENTS 22

COMMERCIALISATION & BUSINESS DEVELOPMENT 24

THE BAKER RESEARCH FOUNDATION 25

BOARD OF MANAGEMENT 26

BAKER SUPPORTERS 27

STAFF 28-31

FINANCIAL REPORT 32-34

PUBLICATIONS 35-38

SUPPORTING THE BAKER 39

www.baker.edu.au 3 ABOUT THE BAKER

The Baker leads the fight against now take for granted. For example, Baker The Baker is a World Health heart disease. Cardiovascular disease is scientists proved that exercise lowers blood Organisation Centre for Australia’s leading health problem as over pressure and they discovered the plasma Cardiovascular Research & Training. 3.6 million Australians suffered from protein that distinguishes between Type I Although we are one of the best cardiovascular disease in 2001. Over the and Type II diabetes. In the future, it is the research facilities in the world, we last decade the prevalence of Baker’s vision to eradicate heart disease. recognise that the fight starts at cardiovascular disease rose by more than The Baker boasts 3 major divisions, home. The Baker is actively 18%, and at a cost of 7 billion dollars 24 research laboratories and more involved in the local community each year, it demands 11% of Australia’s than 220 staff. We focus on both basic and sets it sights on becoming total health care expenditure. and clinical research, a unique and a household name. effective combination. By operating the country’s most During the last 78 years we comprehensive heart research program The major areas of research at the have come a long way, but still our scientists are considered to be Baker are: have much more to achieve. amongst the very best. The Baker is • The risk factors and prevention of It’s the expertise and enthusiasm of recognised internationally as one of the heart disease all our dedicated staff members that world’s leading medical research centres. • Coronary disease, heart attack and will ensure we continue to make a sudden coronary death difference. After all, health means In the past, Baker scientists have • Heart failure the world to us. discovered the medical knowledge that we • Diabetes and its complications

A WORD FROM OUR PATRON

Sir Laurence Muir

I was fortunate to be introduced to the I remember with gratitude my first stress magazine about pets as therapy. With the Alfred Hospital and soon after the test on Garry Jennings’ (current Director help of my son-in-law Dr Edward Donelan Baker Heart Research Institute by Sir of the Baker) bicycle. Urged on by then and some other vets we set up the Delta William Philip and John Habersberger Director Paul Korner, I pushed toward Society to encourage pets as companions. over 40 years ago. For me it has been my limit only to have the machinery go an inspiring and stimulating experience haywire. Garry stopped the proceedings, Dr Warwick Anderson, then at the Baker, to serve with intelligent and highly did lots of chart analysis and then wired spent 2 years in researching the effect of motivated scientists and administrators me up for 24 hours. companion animals on our heart patients. who are dedicated to solving health The results were very favourable and the problems and helping others. Thanks to his care and concern everything veterinarians are continuing to alert the settled down and there have been no community to these advantages. The skill of our research workers has further ‘incidents’ in my 80 years. earned for the Baker a world wide The Baker is not only a world leader in reputation and the partnership with the On the journey back from the UK about medical research; it is peopled and led Alfred is a model in applied research. 20 years ago I read in the QANTAS by warm and caring Australians.

4 PRESIDENT’S REPORT

Norman O’Bryan

I retire from the Baker Board this year buildings, some of which were encourages scientific and social and so this will be my last President’s constructed in the very early part of interaction, because people can see one Report. I thought I should do something the 20th Century when the Baker was another and the spaces are large a little different and take the founded. The “Old Baker Building”, enough to enable research partnerships opportunity to review not only aspects as our former home is now officially and collaborations to form naturally, of the year just past, but also to give called, was a quaint and serviceable as they should do in an organisation you a few thoughts about the Baker’s collection of buildings which did not dedicated to the pursuit of scientific progress in the last decade, where I inspire anyone by their architectural and medical discovery in all of its think it is now and where I hope it will qualities and did not provide a multifarious dimensions. It is a perfect be heading in the future. stimulating or efficient working environment in which to indulge one environment. One of the ‘Old Baker’ of humankind’s greatest aspirations: Annual Reports are hard work for all building’s chief drawbacks, as I the pleasure of finding things out. involved, but a very necessary discipline perceived it, was the fact that it did not which is sensibly imposed upon most encourage collaboration of any sort Despite the fact that we are now well public organisations so that they may because all of the laboratories were and truly settled into this still very new render an account of themselves, both physically constrained and quite home, I think the challenges for the financially and in terms of performance, separate from one another. I regarded Baker remain essentially the same as by explaining what they have been it as a key priority to get the Baker those which I identified when I first doing in the past year and what they housed in better premises because I became associated with the Institute. plan to do in the near future. But it is have always believed in the motive However, our approaches to managing also a good idea from time to time to power of architecture to inspire human and overcoming them are now quite take a wider perspective on the creativity and productivity. There is different. I am pleased to say that I organisation and I shall endeavour to do ample physical and intellectual regard our approach to problem solving this in some measure here. The space evidence of this in Egypt, Greece, and strategic planning for the Baker’s allotted for me in this report is Rome, China and all across Europe. future as much more sophisticated and insufficient to give you a full survey of efficient than it was when I first all of the Baker’s activities, and anyway Probably the most exciting event that arrived. This is due in no small measure Garry Jennings will tell you about most has occurred in my time on the Baker to the combined talents and of the exciting happenings of 2004 and Board is the planning, construction and professionalism of Garry Jennings and what they portend for the future. the move into our new building. It is our senior scientists, Erica Hughes and the ideal home for an Institute like the her administration team and our Board When I first arrived at the Baker in the Baker in every respect. It is open, bright, members. This is my last public late 1980’s it was located in its old cheery and uplifting as soon as you opportunity to applaud them, which I home in Baker Lane in quite worn-out walk in the door. It also actively do wholeheartedly.

www.baker.edu.au 5 Resources additional monies which would provide Tsunami, but because that salvation The most valuable and the scarcest a pool of discretionary funds in the cannot be illustrated in the graphic and resource for the Australian medical hands of the Director to devote to dramatic fashion that occurred in the research community is money. When projects which for various reasons do Tsunami Appeal, it does not resonate I arrived at the Baker it was a block not attract sufficient funding from with the Australian public sufficiently funded Institute of the NHMRC and public sources. It is of the very essence loudly to attract the funds on the scale could rely upon a fixed sum, slightly of independent medical research that given to disaster relief. adjusted in each of the 5 years of the some “blue sky” projects undertaken quinquennia by which the NHMRC by very talented researchers should be One of our great present and future block funded the 5 major Australian funded within Institutes like the Baker, challenges is to convey the medical research institutes. I recall, even when no outside funding source importance and urgency of our when it was first mooted that block can be found for them. The Board fundraising needs to the Australian funding might disappear, that this was rightly considers that we must have the community to ensure that they thought to be potentially the end of confidence and provide the wherewithal recognise the significance to our some of those Institutes. They are all to back the Director’s judgment in such people and to the rest of humanity of still with us, and all bigger and matters from time to time. the work we do. Whilst the Baker has stronger than before. The Baker in a much higher public profile now than particular has flourished in the post- I regret to say that we have not as yet when I first arrived at the Institute, block funded era. It has done this by achieved the objective of providing the I still perceive this as probably the remaining intensely competitive and Baker with a sufficiently large corpus of Baker’s most urgent need upon my very successful in its quest to win peer- capital from which we can reliably earn departure. If you can assist Erica, reviewed grant funding, both within income sufficient to ensure that we can Kristen and our fundraising team in Australia and from overseas, to fund its support science that we believe in but any way, I would urge you to do so. research. Our ability to attract peer- otherwise will not be funded. This, I Ours is a most worthwhile cause. reviewed competitive grants of the think, is the major challenge that the scale we now win is very impressive. Baker now faces. Like the challenge of Our human and material resources to new premises a decade ago, I am sure it undertake our vital research are better But the annual cycle of grant can be overcome. I was struck during than they have ever been. Garry applications, reviews and funding the Tsunami Appeal earlier this year at Jennings is managing to attract, retain requests is a heavy burden for how generous Australians are when and inspire some of the world’s leading Australian medical researchers and a faced with cataclysmic world events like researchers in their respective scientific distraction from their work of discovery. the Indian Ocean Tsunami. The work fields. An example of this is the recent So the Baker Board has striven that we do at the Baker will ultimately appointment of Dr Karlheinz Peter to throughout this period to raise save more lives than were lost in the head the Baker’s Centre of Thrombosis

6 and Myocardial Infarction. Karlheinz Ramaciotti Benefaction), we believe space does not permit me to mention came to the Baker from the University of that some major breakthroughs will be them all here, but their efforts are Freiburg in Germany and is an achieved in this new facility. greatly appreciated. We are lucky outstanding example of an international indeed to have an extraordinarily physician-scientist who was attracted to Our senior scientific faculty has many good humoured and hard working the Baker because of its unique ability stars, some of whom have been team of administration and support to translate basic scientific research already recognised as standing at the staff, all of whom understand that across the spectrum of medical peak of their profession (Garry their mission is to assist in all possible treatment and the testing of new Jennings, Murray Esler, David Kaye ways the progress of the Baker’s discoveries. Karlheinz is a scientist of and Mark Cooper come immediately science. I am constantly struck by whom I am sure we will hear much to mind), others of whom are their energy and dedication to this more in the years to come. knocking at the door of recognition task. Unlike the scientists there are no which we are confident they will soon significant external rewards for them Also during 2004 we significantly receive (they are too numerous to in terms of recognition or upgraded the human and material mention, but “they know who they achievement and so it is important resources which the Baker dedicates to are”!). People are the most valuable that we recognise their excellent its Proteomics and Genomic Research resource of any institution like the efforts in publications such as these facility. This facility operates in the Baker, the value of which is ultimately and that they understand how much Clive and Vera Ramaciotti Centre in the measured in its intellectual endeavour we appreciate their efforts. Baker and is under the joint command and output. Garry Jennings, who was of Professor Greg Rice and Dr Gert recognised by the award of the Order Last, but by no means least, I want to Talbo. They and their very talented staff of Australia in January, is a truly great pay tribute to my fellow Board deliver core proteomic services to leader of this team. I hope that he members. They are a cheerful and scientists operating at the Baker and will stay with this organisation for a tireless bunch, who never refuse even on the AMREP campus generally, but very long time to complete his vision my sometimes unreasonable requests also offer translational proteomic for the Baker as a leading for their precious time and analytical services which provide new discovery international cardiovascular research resources. I know Rob Stewart will platforms for the testing of medical institute at the hub of a major prove an excellent successor and that research hypotheses and the medical research and creative centre the Baker is in the safest and most development and the evaluation of of excellence on the Alfred campus. capable hands. new clinical diagnostics. With the existing and brand new equipment We also have an excellent operations which the Baker has acquired in the and management team under Erica last 12 months (thanks to the Hughes’ capable leadership. Again, Norman O’Bryan

www.baker.edu.au 7 DIRECTOR’S REPORT

Garry Jennings

The end of 2004 completed a period of human resources, IT, commercialisation scientists, or by the excellent transition for the Baker. This fine and and the other important functions that are biotechnology companies based at the gracious lady well into her seventh integral to our pursuit of outstanding Baker. Even more gratifying than the new decade has metamorphosed into the research. Our 3 major scientific themes are facilities however is the cooperation, new Baker, ready to take on the world. prevention of heart, stroke and vascular collaboration and goodwill of the Norman O’Bryan, our President disease with a special focus on diabetes disparate groups from Institutes, University, provided the stewardship for this well and other risk factors, heart failure, and hospital and industry that occupy the administered dose from the fountain of the nexus between heart, stroke and precinct. These have led to joint projects, youth and it is with enormous, albeit vascular disease and the nervous system. sharing of resources, ideas and expertise reluctant gratitude that we note his and this will undoubtedly increase as we intention to stand down from this role Building work has now been completed. get to know each other even better. in the course of 2005. He has given us Not only do we have the wonderful good governance with formidable amenity of the new Baker building and its New technologies introduced this year vision, style, intelligence and that linkage to the Alfred & Baker Medical Unit and the search for new scientists are altogether uncommon grace, common but also two large new floors in the aligned with our overall objective of sense. He constructed an outstanding adjoining building of the research precinct. matching major areas of human need and vigorous Board of Management, a These house the Australian Centre for with our Baker strengths and legacy that will serve us well as we go Blood Diseases, a Monash group led by opportunities. We target only the highest forward. As Sir Laurence Muir, our Professors Hatem Salem and Shaun impact journals to report our work. distinguished Patron can testify we have Jackson. Their research on thrombosis is The Clive and Vera Ramaciotti Centre for a way of keeping past Presidents very complementary with the work of the Proteomics and Genomics Research had involved and we hope this will be the Baker addressing coronary disease and a major upgrade with new, highly case with Norman as he progresses an atherosclerosis. The other new floor has a sensitive equipment for protein detection already stellar career in the law, public, clinical trials platform serving the Alfred and analysis. We have been extremely and family life. campus, Monash, and other triallists in fortunate to attract a whole new team, Victoria and beyond. Through Clinical Trials experienced in the applications of The key elements in our makeover have Victoria and the Centre for Clinical Studies proteomics with Associate Professor involved physical infrastructure, new we are now able to conduct, facilitate and Greg Rice and skilled mass spectroscopist technology, the recruitment of outstanding support clinical trials ranging from the very Dr Gert Talbo. This gives the Baker a scientists, the implementation of the new first time a new therapy is given to people world-class analytical capability to match National Health and Medical Research to large community outcome studies. other flagship capabilities in clinical and Council funding model, and the Hopefully we will soon be testing new translational research, integrative introduction of new systems in finance, treatments developed by our own physiology, and molecular signalling.

8 The community is becoming increasingly of cross link breakers - new therapies for identification of a new target for therapy aware and concerned about the diabetes that prevent damage to the (the arginine transporter), and David Kaye burgeoning increase in risk factors for arteries without affecting sugar levels. has identified a lead compound for further heart, stroke and vascular disease in the Murray Esler, Gavin Lambert and their testing. Geoff Head has another new young. Diabetes and metabolic risk factors colleagues are tackling the obesity compound to test for potential usefulness are of particular concern and the Baker problem from a different perspective and in heart failure and this work, in has built up its already substantial efforts have unique results showing that about collaboration with IMBS has progressed to in the area, particularly through the work one quarter of the body’s production of be the basis of one of a number of new of Mark Cooper’s colleagues in the leptin occurs in the brain. Previously it companies recently formed to Diabetes Complications laboratory and was thought that fat tissues produced this commercialise Baker research. Another the Wynn Department of Metabolic hormone as a mechanism of warning the highlight for our Heart Failure and Cardiology led by David Kaye. Bronwyn brain that we have eaten enough during Molecular Cardiology Division in 2004 Kingwell, Peter Little and Dmitri Sviridov a meal. Murray’s group have also been was the first patient implant of their all had high impact publications, reflecting productively investigating their invention that treats leaking mitral valves. significant scientific advances in the field longstanding interest in the key links The device is inserted using a catheter, of diabetes and metabolism in the course between the brain and the heart that obviating the need for surgery. of this year. Bronwyn’s studies showed the characterise depressive illness, process in which exercise causes glucose panic disorder and other major These are selective vignettes from a large to be taken from the blood into skeletal affective disorders. body of scientific achievements at the muscle for energy production, revealing a Baker in the last year. Much more can be whole new list of possible approaches to Our community is also acutely aware of found in the accompanying 2004 Research lowering blood glucose in people with the rising costs of health care, particularly Report, which is published on our website diabetes. Peter’s group have found a new with an aging community. Heart failure www.baker.edu.au. Formal analysis of effect of an oldish group of drugs in along with other consequences of heart, Baker scientific publications performed preventing atherosclerosis associated with stroke and vascular disease is the greatest during the year shows considerable diabetes. Dmitri has a novel insight into contributor to the cost of health care in increase in productivity with average HDL (the ‘good’ cholesterol) and its the elderly, as well using up hospital beds impact factor (a measure of quality) production by our muscles. Mark and his and expensive and sophisticated increasing to just below 5 at the same team have identified a new AGE therapeutic devices. More importantly it is time as the number of peer reviewed (advanced glycation end product). These responsible for many premature deaths publications increased. The average seem to be involved in the damage to and a huge amount of disability. Our number of scientific manuscripts/ senior arteries that is characteristic of diabetes. research this year on the mechanisms of scientists published was over 6 – a 50% They are also leading world wide testing heart failure and hypertension led to the increase since 2002. Success rates in

www.baker.edu.au 9 competitive peer review grant on normal and abnormal growth of the Commercialisation opportunities have applications continued to exceed heart at Harvard University. increased manifold as illustrated by a national averages and importantly there number of start up companies initiated was an increase in revenue from Sal Pepe hosted a satellite meeting of by the Baker and referred to above. overseas peer review research grants, the 18th World Congress of the There have been hard yards in all of which more than doubled over the International Society for Heart Research, these projects but they will all reap previous year. The establishment of a which drew a coterie of internationally huge future benefits. joint Alfred and Baker Research Office renowned heart researchers to the enabling Heather Gallichio to provide us Institute in August. Three of which are As always, our success has been with a highly efficient level of introduced in the following pages: utterly dependent on the efforts of professional support and grant Professor David Kass, Professor Edward many volunteers. Within the Institute administration has hugely facilitated Lakatta and Professor Roberto Ferrari. these include members of various these results from the labs. One Many other distinguished visitors graced committees such as Scholars interesting and popular initiative from our Institute during the year and we (Chair Walter Thomas), Equipment Murray Esler and Heather and her team hosted a number of other scientific (Chair Phillip Kantharidis, who also has been the introduction of a monthly meetings including the Australian High runs our excellent seminar program), research prize to the laboratory with the Blood Pressure Research Council annual Grants (Chair Colin Johnston) and highest impact publication. scientific meeting. Science Council (Murray Esler). However, there are many more An extensive international search led us We are engaged in a people business volunteers who in the cause of to identify Professor Karlheinz Peter, an and much of Erica Hughes’ effort on scientific excellence contribute extra interventional cardiologist as one of the the operations side was directed time and hard work on our behalf. outstanding figures in translational towards revising and renewing our Our President and Board provide us research on thrombosis. Karlheinz approaches to staff related matters not only with good governance but joined the Baker at the end of 2004 such as classifications, remuneration, also a whole lot more advice and and will establish a new Centre, which conditions, payroll and policies. At the support, skill, energy and tolerance. will develop novel methods of same time we have had major projects We are grateful to all our staff, preventing thrombosis and its in IT and in Occupational Health and supporters, volunteers, stakeholders consequences. We thank the Helen Safety. Fundraising is not getting any and allies who make it all possible. MacPherson Smith Trust for supporting easier with so many worthy causes to the acquisition of Professor Peter. Other support but Kristen Boschma and her new arrivals at the end of 2004 include team have been laying the foundations Julie McMullen who has been working for a major capital raising effort. Garry Jennings

10 ORGANISATION CHART AS REPRESENTED BY THE HUMAN HEART

www.baker.edu.au 11 Although the heart health of people in Melbourne and Australia remains the main focus for the Baker, it is important to acknowledge that the fight against heart disease is a global one.

The Baker Heart Research Institute is regarded internationally as a vital component in the progress made towards the prevention of heart disease world wide. Its contributions have been many and significant and its science is sought after in the pursuit of new and innovative research methods.While groundbreaking revelations have often placed the Baker in the limelight, it is the long term commitment and consistent development that has earned the Baker its reputation as a leader in cardiovascular research.

The drive for Baker scientists comes from the belief and knowledge of their potential to improve people’s quality of life.Together with the best researchers in the world they continue to strive towards an eventual eradication of the world’s leading cause of death.

12 PROF. DAVID A. KASS M.D.; F.A.H.A U.S.A – Abraham and Virginia Weiss Professor of Cardiology – Professor of Biomedical Engineering Johns Hopkins Medical Institutions “The John Hopkins Hospital, where I am, halfway around the world from Melbourne, is very familiar with the leadership role that’s gone on here at The Baker Heart Research Institute. Many of the members of The Baker have played pivotal roles, particularly in our understanding of arterial disease, hypertension, heart failure, and diabetes.”

PROF. EDWARD G. LAKATTA M.D. U.S.A – Senior Investigator – Chief, Laboratory of Cardiovascular Science and Chief, Cardiac Function Section Gerontology Research Center, National Institute on Ageing, National Institutes of Health, Baltimore, USA

“For us to conquer heart disease we have to understand about the aging of hearts and blood vessels, and that’s what’s being done in such a superb way by the investigators here in Melbourne’s Baker Heart Research Institute.”

PROF. ROBERTO FERRARI ITALY – Professor and chairman, Department of Cardiology, University of Ferrara, Italy “I’m really honoured to be associated with the Baker Institute because we are aware of their research in Europe and I’m sure we’ll have a future relationship in (our quest) to prevent heart attacks in human beings.”

www.baker.edu.au 13 SCIENTIFIC OVERVIEWS

HEART Cardiology Division David Kaye

The Cardiology division brings start-up company, V-Kardia, to develop years lost to morbidity and mortality researchers with a diverse range of a device to deliver targeted gene in our society. The Cardiology skills together to study the heart in therapy treatments to the heart. division harnesses the talents of health and in disease. The division, each of its members to work toward headed by Wynn Professor David Kaye, Some members of the division cross the larger goal of preventing spans molecular cardiology labs who traditional scientific boundaries, such cardiovascular disease in Australia conduct basic research into the ‘nuts as Dr Assam El-Osta, whose human and around the world. and bolts’ of how the heart works, epigenetics laboratory has ongoing through to clinical researchers working projects with other division members To this end, the Cardiology division with patients awaiting heart transplant. to look at the role of structural has benefited greatly from the very changes to genes in a number of generous support of Professor Victor

Key molecular mechanisms of processes in health and disease. Wynn and the Atherosclerosis hypertension, heart cell death and Likewise, the experience with small Research Trust (based in the UK). cardiac hypertrophy are being animal models and microsurgical skills Such support has allowed investigated by Dr Wally Thomas and of Dr Xiao-Jun Du are being applied to considerable progress to be made in Associate Professor Liz Woodcock. projects across the entire division and our extensive program of research the larger institute as a whole. directed at understanding the

At a more clinical level, Dr Jaye Chin- Dr Rebecca Ritchie also acts to connect metabolic basis for heart failure and Dusting investigates changes occurring the cardiology division to other its underlying causes. in aging arteries, work of special researchers within the institute with relevance to Australia’s aging her work looking into the effects of For more detail on our population. Dr Sal Pepe investigates diabetes on the muscle of the heart. research, please go to novel surgical techniques, and Dr John www.baker.edu.au Power conducts applied cardiovascular The Cardiology division brings for our research report. research into devices to assist with together such diverse groups in order heart failure. Highlights this year to address the ‘big issues’ in heart include the first patient implants of a research - diseases such as heart percutaneous mitral annuloplasty failure, arrhythmia and heart attack,

device, a device to fix leaky mitral which require a major public health valves, and the formation of a Baker focus and are a leading cause of

14 BRAIN Cardiovascular Neuroscience Division Murray Esler

The brain-heart link is the primary leptin release. This discovery is highly brain to investigate neural mechanisms focus of research for this Division, important because leptin is an of this form of hypertension. investigated both in humans and in important regulator of body weight, experimental animals. The Division making it the focus of a lot of attention • Studying the neural pathophysiology incorporates the Human in the fight against obesity worldwide. of Postural tachycardia syndrome Neurotransmitter Laboratory, under (POTS) the leadership of Dr Gavin Lambert • Investigating the role of the This common but enigmatic disorder is and the Neuropharmacology sympathetic nerves in renal characterised by sufferers displaying a Laboratory, headed by Associate hypertension racing heart and blackouts upon Professor Geoff Head. There is increasing evidence that standing. The cardiovascular Our research findings support the sympathetic (stimulant) nerve activity is neuroscience division is investigating importance of psychological important in the development of the control mechanisms of the brain mechanisms and mental stress in heart hypertension, heart failure and renal circuitry involved in POTS. Research disease and high blood pressure. failure. We have shown that the relative focuses on the role of noradrenaline, role of the renal sympathetic nerves in one of the brain’s ‘messenger

• Investigating the neurobiology of causing angiotensin-dependant chemicals’ or neurotransmitters. Obesity-Related Hypertension hypertension diminishes with the Significant discoveries in this area This research aims to find a rational development of the disease. include the discovery of an epigenetic basis for the treatment of Obesity- abnormality in the noradrenaline Related Hypertension through ongoing • Analysis of the neurobiology of transporter gene in POTS patients, studies into the way in which the ‘neurogenic’ essential hypertension which may be the cause of the disorder. development of obesity causes blood We have previously shown that this form pressure elevation. Significant of high blood pressure is initiated and • Exploring the mechanisms of heart discoveries in this area include the sustained by overactivity of the risk in depressive illness finding that leptin, a hormone known to sympathetic nervous system. In It has long been known that depressive be secreted by fat tissue, is also collaboration with Professor Graeme illness materially increases heart risk, yet produced in the human brain. Leptin Jackson of the Brain Research Institute at the precise mechanisms by which this release from the brain is markedly Austin Health, we will apply functional occurs are yet to be fully explained. The increased in human obesity, accounting Magnetic Resonance Imaging (MRI) cardiovascular neuroscience division has for more than 25% of whole body methodology of selected regions of the found that in approximately 40% of

www.baker.edu.au 15 depressive patients, the level of activity between the brain and the heart, the INTERNATIONAL COLLABORATIONS in the sympathetic nerves of the heart is work of this division also extends to the Associate Professor Geoff Head’s lab markedly elevated to the level seen in local community. Sufferers of panic hosted Dr Elena V Lukoshkova from the patients with terminal heart failure. disorder are often unaware that they National Cardiology Research center in This discovery may yield an explanation have a relatively common treatable Moscow, Russia. Dr Gavin Lambert’s for how depressive illness constitutes a illness, believing that they are either lab hosted Dr Klemens Fellner from the risk factor for heart disease. “going mad” or in grave danger of Faculty of Mathematics, University of sudden death. By volunteering for studies Vienna, Austria. International

• Investigating the neurophysiology of such as those into the biology of panic collaborators include Dr Phil Gold, panic disorder disorder, sufferers in the local community a distinguished depressive illness Abnormalities in the gene which codes often gain a better understanding of the researcher from the National Institutes for the noradrenaline transporter have causes of panic disorder, the level of of Health, USA, and Professor Mona also been described in patients suffering heart risk (which in the majority of Soreq, an international figure in panic disorder. Our work adds to the patients is, in fact, negligible) and neurogenetics, based at the Hebrew growing knowledge of the mechanisms potential ways to deal with the condition. University, Jerusalem. of how panic disorder contributes to The cardiovascular neurosciences increased cardiovascular risk. Part of this division has benefited from collaborations For more detail on our increased risk may be mediated by with The Institute For Molecular Bioscience research, please go to adrenaline, second neurotransmitter of in Queensland, studying novel peptides www.baker.edu.au the sympathetic nervous system. isolated from snake venom as a potential for our research report. We have recently shown neurobiological treatment for heart failure. We have abnormalities in adrenaline signalling in established a Baker spin-off company, sympathetic nerves in patients suffering ElaCor, to develop these novel therapies. panic disorder. Work is ongoing investigating the effects on heart risk of two different treatments for panic disorder, cognitive behavioural therapy and selective serotonin reuptake inhibitor (SSRI) medication. As well as having a global impact on

the understanding of the interactions

16 VESSELS Vascular Division Mark Cooper

The Vascular Division is a diverse group have developed new treatment of the compliance or stiffness of large of laboratories that are all engaged in strategies to slow the progression of arteries. As one ages, one’s arteries get the exploration and identification of the diabetic renal disease. This group has stiff and it is now known that this is a causes, processes, effects and new also expanded their interests to the risk factor for subsequent heart disease. treatments of vascular disease. vasculature, examining why diabetes leads to accelerated atherosclerosis. Several years ago this group

The major grouping in the division Indeed, up to 70% of people with demonstrated for the first time that this studies diabetes, and in particular, diabetes die from cardiovascular vascular stiffness aggravates coronary its vascular complications. This group is disease, mainly from heart attacks and artery disease leading to heart attacks. headed by Professor Mark Cooper who strokes. In a model of experimental This group has recently shown that there leads a team of over 20 researchers diabetes-associated atherosclerosis, are certain genetic factors, particularly focusing on the vascular, renal and which develops spontaneous fatty variations in genes coding for the cardiac complications that occur in streaks and plaques in the vessel, this structural components or building blocks diabetes. With the growing number group has identified that specific of artery walls that increase the risk of of obese people and lack of exercise, treatments useful for the kidney are large artery stiffening leading to rises in people who develop Type II diabetes also helpful in retarding atherosclerosis. systolic blood pressure and ultimately are now doing so earlier, whilst middle coronary artery disease. aged. This has created an increasingly The Clinical Physiology section, led by important public health problem in Associate Professor Bronwyn Kingwell, The Vascular Biology group undertakes Australia and throughout the world. has two major areas of interest. research on atherosclerosis and vascular Diabetes, particularly late onset or Type II changes caused by genes, hormones,

However most people with diabetes, diabetes, is a major health problem, as diet, exercise, ageing, high blood both Type I (juvenile) and Type II (adult), outlined earlier. It is well known that pressure and drugs. Atherosclerosis is nowadays do not die from the exercise improves blood glucose control the formation of lipid fatty deposits in metabolic abnormalities of diabetes but in diabetes and this laboratory has now the vessel wall. When this occurs in the from cardiovascular-related unravelled the mechanism by which this coronary vessels it leads to heart complications. This group has a occurs. This understanding will allow us attacks, when it occurs in the brain it longstanding international reputation in to develop drugs that mimic the action can lead to stroke. Deposition of diabetic nephropathy which leads to of exercise. The second area of interest of cholesterol, the major component of the kidney failure and over the last year this laboratory involves the assessment lipid plaques in the vessel is a result of

www.baker.edu.au 17 an imbalance between delivery of in lowering cholesterol. Also, at a abnormal and sticky proteins, and is cholesterol to the vessels and removal clinical level the Experimental and currently translating these exciting of excess cholesterol. Preventing the Human Vascular Biology group are laboratory results to the clinic. formation of cholesterol and therefore looking at the relationship between delivery of cholesterol to tissues has lipids, the endothelium (vessel lining) Dr Little’s group explores particular been the way that the group of drugs and atherosclerosis. structural proteins within the vessel known as statins work to successfully wall known as proteoglycans and how lower cholesterol and prevent heart The high glucose levels in diabetes leads they are altered by diabetes. attacks. The Lipoprotein and to specific irreversible chemical reactions This group has shown that certain Atherosclerosis laboratory is aimed at between the excess sugar and proteins drugs modify the blood vessel determining pathways involved in such as haemoglobin and other properties and this has potential removal of cholesterol from the vessel structural proteins. This process is called applications for reducing diabetes- wall and looking for ways of enhancing advanced glycation, and results in the related vascular complications. its removal. Such studies may ultimately accumulation of these glucose modified lead to either an alternative to statin proteins at many sites such that there is This research into diabetes is part therapy or an additional drug to treat disruption of normal tissue structure and of a major centre grant recently atherosclerosis. Similarly, the Cell function. The Glycation and awarded by the Juvenile Diabetes Biology group are also trying to Complications group has shown that Research Foundation International, understand the development of the these molecules not only cause based in New York. fatty lesions in blood vessels and the structural changes but also activate processes responsible for the many harmful processes in the heart, For more detail on our progression of the lesions to the stage kidney and blood vessels. The group has research, please go to where they rupture and cause heart recently identified the role of a new www.baker.edu.au attack or stroke. At a clinical level, the treatment which dissolves these for our research report. Cardiovascular Nutrition group is focussing on investigating nutrition and food related strategies that may contribute to cardiovascular health. They continue to explore, in large clinical studies, the role of plant

sterols (which are available in foods)

18 CORE FACILITIES

The various Baker core facilities are fractionation of sample proteomes the Monash University Central and crucial to the success of the scientific and analysis by direct mass Eastern Clinical School based at The research programs running within the spectrometer. The platform will Alfred. Use of the library has Institute. Access to these different greatly increase the Centre’s continued to grow, especially the use facilities allows an efficient and cost biomarker discovery capacity. of the electronic services provided to effective mechanism by which Institute staff and students. Extensive training scientists receive essential scientific • The AMREP Education Centre was a has been provided to library users to support for their research. Some busy venue for the Baker Institute's encourage and support the use of highlights for 2004 were: regular scientific and organisational these web-based resources. meetings in 2004. Situated between • The ongoing development and the Ian Potter Library and the Baker • An important support service is the upgrading of the Clive and Vera building it consists of large seminar Precinct Animal Centre (PAC) under Ramaciotti Centre for Proteomic and rooms, class rooms and smaller the leadership of Debbie Ramsey and Genomic Research facility. A Bruker meeting rooms. It is a flexible David Spiteri. This is a purpose built Autoflex MALDI TOF mass arrangement, which has excellent facility for breeding and housing spectrometer, suitable for rapid audiovisual equipment available. laboratory animals used for medical protein identification, has been A diverse range of Baker research research. The environmental commissioned. This instrument is seminars and other meetings were conditions within the PAC ensures currently providing peptide finger held in the Centre during the year, the highest standards of animal printing analysis service and PSD many involving invited international welfare and meets the varying needs sequencing. In addition, a Bruker HCT speakers, such as the ‘Aging Heart of the Baker researchers as well as Plus ESI- Ion Trap mass spectrometer and Vessels’ meeting in August 2004. those of other Precinct partners. has been purchased to increase the This high profile satellite meeting to Furthermore, they enable the Baker Centre’s ability for protein/peptide the 18th World Congress of the to maintain the highest standards identification and de novo International Society for Heart and meet all the regulatory sequencing. The existing GE Research allowed the Baker to requirements. The PAC offers a Healthcare robotic spot handling benefit from hosting world-renowned number of advantages. The rooms workstation and Ettan MALDI mass scientists and clinicians during the were designed for flexibility in terms spectrometer both have undergone 3-day meeting. of the species that can be significant upgrades to enhance high- accommodated, and also readily throughput functionality. To • The Library provides library and adapts to projects using infectious or complement the Centre’s proteomic information services to staff and non infectious animal models under capacities, a Bruker ClinProt platform students of the Baker Heart Research various levels of biocontainment. has been installed. This magnetic Institute, The Alfred Hospital, The bead-based system allows rapid Burnet Institute and departments of

www.baker.edu.au 19 • Advanced digital imaging at the adenoviruses. This year saw the demanding methodologies available Baker encompasses many types of successful production and purification to other laboratories. During 2004, microscopy. The core imaging system of an adeno-associated virus, the this Core Facility via Experimental is our confocal microscope which production and purification of Cardiology continued to provide enables scientists to visualise live cell adenoviruses for six external collaborative support by performing activity in three dimensions and collaborators, as well as an microsurgery and determining observe changes through time. The increased number of internal users cardiovascular function as well as system has contributed to a number of the facility. methodology training for groups of recent publications. Other key including Molecular Cardiology, microscopy systems and facilities • The Baker has stayed abreast of Human Genetics, Cell Biology and allow for specialised and routine recent advances in cardiovascular Vascular Pharmacology. image analysis and for the research with our Mouse preparation and editing of images for Surgery/Cardiology Core Facility. The COMMUNITY PROGRAMS publication and presentation. selective use of genetically • The Alfred Baker Medical Unit manipulated animals allows us to (ABMU) is a collaborative research • The Adenovirus/Gene Delivery Core determine the role of significant unit between the Baker and the Facility provides expertise and genes and proteins in cardiovascular Alfred that has been established for amenities to allow Baker physiology and disease. Because the over 50 years. The unit provides a scientists, as well as external mouse is the common choice of unique smooth interface between collaborators, the capacity to species for this type of research, medical research and clinical generate and purify adenoviral determining mouse heart and research. It is a bridge between constructs. Adenoviruses and adeno- vascular function and reproducing “bench top to bed side”. This division associated viruses are unique tools cardiovascular diseases in small conducts the preclinical and clinical for infecting difficult to transfect cells animals have become important trials of therapies developed in this both in culture and in vivo and have research approaches. The Mouse and other Baker divisions, as well as particular utility for cells and tissues Cardiology Core Facility has been those commissioned from outside. of the cardiovascular system. The providing collaborative support to The Baker was the first Australian facility includes a self-contained, other groups at the Baker in World Health Organisation state-of-the-art cell culture suite on conducting cardiovascular research Collaborating Centre for Research the 2nd floor of the Baker Tower with using mice. A range of functional and Training in Cardiovascular Diseases. biosafety cabinets, cell culture and microsurgical methodologies incubators and fluorescent have been up and running at • The Cardiovascular Disease microscopy. Expertise is available in Experimental Cardiology Laboratory, Prevention Unit (CVDPU) is engaged strategy, cloning, recombination, which via the Mouse Cardiology in both domestic and international production and purification of Core Facility, makes these

20 heart disease prevention projects. involved in a broad range of research countries and providing medical The CVDPU also coordinates, studies, including collecting samples research training. This will enable the conducts and analyses major state for The Alfred & Baker Gene Bank, provision of better heart disease wide, national and international in addition to the critical role of prevention, treatment and education clinical trials. A number of large recruiting subjects for ABMU studies. in these regional countries. international clinical trials were Recently, the Clinic has studied the conducted at the Baker in 2004 genetic causes of hypertension and • The Alfred and Baker Gene Bank is including REACH and ON TARGET audited secondary prevention an important research initiative of studies. Numerous smaller clinical measures for heart attack and the Baker Heart Research Institute. trials were also carried out. The cardiac surgery patients. Research The aim of the Gene Bank is to CVDPU was appointed by the continues into better methods of collect samples of blood or tissue in Australian Society of Cardiothoracic defining risk in healthy subjects. order to study the genetic Surgeons as a Data Management determinants of cardiovascular and Analysis centre for a project to • The Baker is a World Health disorders. This research may lead to identify key performance indicators Organisation (WHO) Collaborating important new discoveries in drug for cardiac surgical outcomes. As a Centre for Research and Training in treatment and prevention of heart result of its demonstrated Cardiovascular Disease. The attack and stroke. The Gene Bank effectiveness in 2004, the program Appointment by the WHO to the relies on blood and tissue donations has expanded with other national Baker was the first of its kind in from healthy volunteer subjects in centres joining the Baker in using Australia. Currently, the Baker has addition to people who have these models to predict outcomes two overseas projects with the WHO, already had a heart attack, stroke or after cardiac surgery. one in Vietnam and one in Mongolia. have high blood pressure, high The occurrence of heart disease in cholesterol or other risk factors for • The Risk Reduction Clinic is one way these and many Asian countries has cardiovascular disease, for example in which our expertise in reducing escalated in the past few years a family history of heart disease. the risk of heart disease is made mainly due to the erosion of Currently over 4000 volunteers have directly available to the community. traditional lifestyles with the provided samples for the Gene Bank The service is free of charge and is increasing pervasion of Western and it is well on the way to conducted by highly trained clinical influences. The joint WHO and Baker becoming an important resource for nursing and technical staff. The staff projects involve assessing the the discovery of new ways to treat at the Risk Reduction Clinic are prevalence of heart disease in these and prevent heart disease. If you would like further information on the ABMU, the Risk Reduction Clinic or the Gene Bank please call (03) 9276 2000.

www.baker.edu.au 21 GRADUATING STUDENTS

proteoglycan binding to LDL and my leptin to enter the brain, its principal future work will aim to extend this to site of action. When I tested this the discovery of new agents proposition directly, by looking at the specifically targeted at this process. amount of leptin in the blood as it enters and leaves the brain, I found NINA EIKELIS – that there was net release of leptin Project Summary from the brain, rather than the Investigation of the Biology of expected uptake from the blood. This JULIE NIGRO – Adipocyte, Brain and Cardiac Leptin finding provided impetus to study Project Summary and of the impact of Leptin on the leptin expression in the human brain. The role of PPAR-alpha ligands Sympathetic Nervous System. In a study conducted with the (fibrates) in the regulation of vascular assistance of the Victorian Institute of smooth muscle proteoglycan synthesis Forensic Medicine I have shown that and structure the leptin gene is expressed in the human hypothalamus, the area of the Elevated LDL (“bad”) cholesterol and brain which controls bodily functions. triglycerides (fats) in the blood Leptin resistance has been claimed to contribute to fatty deposits in the blood be a major cause of obesity in vessels of the heart. This process is humans. A major component of this called atherosclerosis or “hardening” of resistance has been suggested to be the arteries. Atherosclerosis begins During my PhD candidature, I have likely due to an impaired transport of when the cholesterol is trapped in the been involved in experimental work, leptin across the blood-brain barrier. blood vessel by “sticky” molecules aimed at elucidating the role of leptin However, our observation of leptin called proteoglycans. in obesity and obesity-related disorders. production by the brain itself makes This work has involved both clinical untenable this notion, and may lead in My research aimed to determine and basic-science research future to major advances in the whether or not fenofibrate (a new drug encompassing tissue-based techniques prevention and treatment of obesity. which is prescribed to patients with and the use of animal models. diabetes to control blood lipids) has STEPHANIE DE DIOS – direct effects on proteoglycans Leptin is a hormone produced primarily Project Summary produced by cells in the blood vessel, by adipocytes (fat cells), which in rodents Anti-Atherogenic Actions of separate from the actions on is thought to play an important role in Thiazolidinediones on Human Vascular triglycerides and cholesterol. I have body energy balance. Leptin acts in the Smooth Muscle Cells published my findings with gemfibrozil brain to inhibit appetite and to promote (a similar drug to fenofibrate) and more thermogenesis, in part by activating the The focus of my PhD studies was recently with fenofibrate showing that sympathetic nervous system which directed on the actions on the blood these drugs alter the biochemical stimulates bodily functions. In a major vessels of the newest class of properties of the proteoglycans making rethink of established medical teaching, glucose lowering agents for the them less “sticky” and the result is we now know that leptin is produced in treatment of Type 2 diabetes. These reduced attraction or binding to LDL. sites other than adipose tissue. This was a drugs are called thiazolidinediones particular focus of the research during my (TZDs) and may have atherosclerosis- My work makes a significant PhD candidature, where I studied leptin reducing properties on the smooth contribution to the field of diabetes production in the human brain and heart. muscle cells in blood vessels. The and atherosclerosis because this is studies investigated the effects of the first demonstration of a regular Traditional wisdom holds that leptin TZDs on the proliferation and prescription drug preventing resistance exists in human obesity and migration of vascular smooth muscle atherosclerosis by reducing that this is a consequence of failure of cells regarding restinosis, the

22 scarring that occurs in an artery allow rapid and robust measures of Despite the clear and present danger after a scaffold-like stent is inserted urotensin mediated cardiac hypertrophy of diabetes, our understanding is to maintain blood flow past a and related signalling pathways. severely limited of the mechanisms plaque. Studies were also carried I showed for the first time that that contribute to organ injury out on proteoglycan biosynthesis urotensin potently causes hypertrophy resulting from diabetes, such as and proteoglycan/LDL binding, of cardiomyocytes and identified the blindness, amputations, kidney failure which investigated the production various post-receptor signals involved; and heart disease. My research has and binding of cellular proteins this research lead to two high impact concentrated on the formation of (proteoglycans) produced by human papers, one in Circulation Research Advanced Glycation End products or vascular smooth muscle cells to (impact factor, 10.1) and the other in AGEs as they are significantly called. low density lipoproteins (LDL or Molecular Endocrinology (impact factor, These are formed by a reaction cholesterol) in relation to 5.7). The novelty of this work was also between proteins and sugars within atherosclerosis. recognised by an invitation to write a the body, and the longer-lived the review article for the prestigious Trends protein is, the more likely it will DONE ONAN – in Endocrinology and Metabolism become AGE-modified. This reaction Project Summary (impact factor, 7.9) and acceptance to leads to a change in the shape and Cardiovascular and Regulatory Aspects present this work at national and function of AGE-modified proteins. of the Urotensin-II Receptor international meetings. I also delved An example of this is the AGE even deeper into the subcellular modification of collagen that results mechanisms by which urotensin acts, in a tissue having reduced solubility, studying receptor phosphorylation and flexibility and a lower breaking point. internalization of UT-Rs. I made the key This may be readily appreciated by observation that the UT-R is surprisingly everyone when they consider the recalcitrant to the generally accepted toughness of an old sheep compared mechanisms of ligand-induced receptor with the tenderness of lamb. deactivation, offering a possible Although AGEs contribute to some of explanation for the very strong and the physiological changes that we In September 2004 , I completed my prolonged actions of urotensin recognise as signs of ageing in the PhD candidature under the supervision observed in the body. human body (such as cataracts and of Dr Walter Thomas in the Molecular stiffness), the excess of sugars in Endocrinology Laboratory at the Baker diabetes hastens the reaction, Heart Research Institute. My thesis meaning that not only are long-lived focused on the recently discovered proteins more heavily modified but urotensin receptor system, which also that shorter-lived molecules comprises a hormone which has effects become targets for advanced on blood vessels, urotensin II, and the glycation. The importance of AGEs in molecular machinery by which diabetes is best illustrated by the urotensin works in the cell, via its G fact that it has been possible to protein-coupled receptor, GPR14 (or MERLIN THOMAS – block the formation of AGEs in UT-R). Using molecular and cellular Project Summary experimental diabetes and prevent approaches, I investigated two major The growing epidemic of diabetes will irreversible organ damage, without aspects of this system – 1) its capacity ultimately affect more people that any having to control sugar levels. to cause growth of heart cells ( cardiac other disease in the Western World. Over Indeed, when AGE-modified proteins hypertrophy), which may explain the a million adult Australians currently have were infused into animals many of relevance of urotensin to heart failure diabetes and twice that number again the changes of diabetes and ageing and death in humans; 2) the signalling are at high risk of developing diabetes were generated - without elevated and regulatory processes activated by in the next 5–10 years. Diabetes – and, sugars. For the millions who struggle urotensin via the UT-R. I developed a more importantly, the complications to try to control their sugars every model system of cultured neonatal arising from diabetes - are set to day, an understanding of this cardiomyocytes infected with an become one of Australia’s most costly pathway will provide an important adenovirus expressing the UT-R to and significant public health issues. adjunct to their care.

www.baker.edu.au 23 COMMERCIALISATION AND BUSINESS DEVELOPMENT

Commercialisation involves taking our In August 2004, the Baker, in Finally, the Cardiac Devices Development research to the market, be it through conjunction with the Institute for Group funded through the Baker’s undertaking clinical trials, licensing our Molecular Bioscience (IMB), formed our commercialisation seed fund and under inventions to biotechnology or first “spin-off” company, ElaCor Pty Ltd. the leadership of Dr John Power, pharmaceutical companies or The rationale for this activity was to continued their work on the development establishing businesses, which will provide a commercialisation vehicle to of a range of interventional cardiac further develop our research inventions support a research collaboration devices. Several patent applications have through to drug development. The year between Associate Professor Geoff Head been subsequently filed to protect this IP, 2004 was very exciting and rewarding of the Baker Heart Research Institute and the year concluded with the in the Commercialisation Office with and Professor Paul Alewood of IMB. incorporation of another new start up several commercialisation ‘firsts’. Working together, these scientists have company, V-Kardia Pty Ltd, to described the effect of natriuretic commercialise these developments. Licensing and start up company peptides on blood pressure and heart In December 2004, V-Kardia successfully formation are two pathways typically rate. This research has potential entered into a research and collaboration utilised to exploit and commercialise our commercial implications for the agreement with a US based intellectual property. treatment of hypertension and biotechnology company to further develop congestive heart failure. a gene therapy delivery system targeted In 2004, the Baker concluded at the treatment of heart disease. negotiations for licensing agreements Since incorporation, ElaCor has with two major global pharmaceutical successfully attracted $250,000 The Baker continued its association companies. Discussions regarding a third funding from the AusIndustry with two clinical trial businesses. licensing agreement with a U.S. Biotechnology Innovation Fund (BIF) The first, Clinical Trials Victoria is a biotechnology company were initiated in and an $80,000 ISUS grant from the consultancy company that provides 2004, and finalised in early January 2005. Queensland State Government for services to members, biotechnology non-scientific costs. and pharmaceutical companies in the areas of regulatory support, quality Also in 2004, the Baker signed a patent assurance, data management and acquisition agreement with Dia-B Pty marketing. The Baker is also a part Ltd, a company formed as a vehicle for owner of the Centre for Clinical research into diabetes and obesity. Studies, a business that specialises in Dia-B will fund its research portfolio via undertaking clinical trials for industry capital raisings, and listed on the and academic partners. In April 2004, Australian Stock Exchange (ASX) via an the Centre opened its new 24-bed Initial Public Offering (IPO) on 24 Phase 1 clinical trial facility at the January 2005. The agreement with Baker’s premises. This state of the art Dia-B will provide almost $500,000 over facility is the first in Victoria and one a two-year period to advance the CDA1 of the major centres in Australia project, which is supervised by undertaking specialise phase one Dr Zhonglin Chai. drug trials.

24 THE BAKER RESEARCH FOUNDATION

YOUR HEART IS IN THE PROFESSIONALS BY THE BOTTLE BAKER VOLUNTEERS RIGHT PLACE Our inaugural Professionals by the Our loyal volunteers assisted the We would like to thank each and every Bottle event was held in July and was a Baker with more than 600 hours of one of our supporters who made a gift great success. Fifteen generous their time in 2004. They opened wine, in 2004. The Baker has a very winemakers from the medical, legal and filed, did data entry, stocked our committed and loyal group of ‘friends’ business professionals provided their bandages, were always helpful, who have been a part of our family for wine for the event. James Cuthbertson manned the lift, greeted guests, many years. In addition, we welcome of Murrindindi Winery was voted the tracked our chemicals, were always everyone who has recently become Baker Winemaker of the Year. welcoming, counted Christmas cards involved with the Baker. and spoons, served tea and coffee, shredded paper and photocopied. We are fortunate to have We thank them all for their time, a group of 123 very their smiles, and their commitment special friends who have to the Baker. chosen to leave a gift in their Will. It is wonderful By supporting our research, through that we are getting to attending events, making financial know them all in their contributions, or volunteering, you are lifetime. No matter how all helping to make a difference. you have chosen to support the Baker, you are helping our WINE LOVER’S DINNER We thank you – scientists find the answers to This event, held at the Melbourne Club, all your hearts are in cardiovascular disease. continues to be a highlight of our event the right place. calendar. This was a record year for For details on how you During 2004 we held several special attendances and whilst our guests can support The Baker events, which gave our supporters the enjoyed fine food and wine in beautiful see page 39. opportunity to meet our scientists, learn surroundings, they also made it a record more about our work and in many cases year for fundraising. simply enjoy themselves. Here are a few of those events: PETER BROCKLEHURST CONCERT A sell-out crowd enjoyed an evening THE GREAT DEBATE of delightful music from Peter Mark Mitchell compered a very Brocklehurst and Margaret Orr – entertaining debate between our male accompanied by Maestro Vladimir Vais and female scientists in March 2004. on piano. Held at Christ Church in The topic tackled was “That women are South Yarra, it was a most enjoyable healthier than men” and it provided a event. Peter and Margaret sang most stimulating and enjoyable evening wonderfully and our guests all agreed for all who attended. it was a special night.

Peter Brocklehurst

www.baker.edu.au 25 BOARD OF MANAGEMENT

BACK ROW (L-R) Professor Graeme Ryan, Mr Peter Scott, Mr Norman O’Bryan SC (President), Professor Garry Jennings AM, Mr Robert Stewart FRONT ROW (L-R) Ms Paula Dwyer (Honorary Treasurer), Mrs Erica Hughes, Mrs Anita Furnell ABSENT Professor Ed Byrne, Mr Greg Hywood, Professor Richard Smallwood AO, Mr Philip Munz, Dr Gerard Johnston (Vice President) 26 Ms Paula Campbell-Tuckfield BAKER SUPPORTERS

Here is one young man whose Endowments Peter Swindells OAM Noel & Mary Myers Palace Cinemas heart is very much in the right - Hazel & Pip Appel Fund L L Thompson Eileen Nihill Penbro Estate Winery place. Neil Waters (from Gippsland) - The Baker Foundation Harold Edward Vivian Valmai Notley Pettavel Winery & Restaurant headed off on the Kokoda Trail with - Estate Lindsay J Baldy Tony & Joan Weber Edward Percy Oldham Pfeiffer Rutherglen Estate nine mates in August 2004. Before - Bell Charitable Fund Carmel Opray Random House Books he left, he held a Golf Day in - Thomas, Annie & Doris Burgess Baker Bronze Club Duncan Palm Shantell Wines Wonthaggi and a Black Tie Dinner - William Buckland Foundation Alan Abbey Louis Partos Simply Sensational Catering and Auction – all to raise money for the - Grace & Herbert Foulkes Beryl Allison Gerard Jean Paruit Events Charitable Trust Lawrence Armstrong Diana Peatt Baker. Neil had a quadruple heart Strathewen Hills Vineyard - Estate Kenneth W Hesse Stuart & Margaret Barker Bob & Sandie Pender by-pass at just 33 years of age and Yarra Brook Estate - Estate George F Little Settlement J E Belcher John A Perry Wesley College took this opportunity to show his - M A & V L Perry Foundation Robert Bell David & Diana Plant appreciation to the researchers - George Thomas & Lockyer Len & Leila Bentley Mark Plunkett Bequests who helped save his life. He raised Potter Trust Donald & Suzanne Birch MG Pollock - Estate Frances Hilda Parkinson more than $21,000 for the Baker. - Emily Elsie Elizabeth Stewart I G Bird A & R Proudlock - Estate E W Wortley Thank you again Neil – we hope L Bitterfeld Joan Ray - Estate Eric W Tobin you know how special you are. Scholarships & Fellowships James Bland Eric Graham Reid - Estate George Llewellyn Jones - Allan Williams Trust Fund Gwendoline Bowman Noel & Gloria Reid - Besen Family Foundation Joy Bromley Bobbie Renard - Estate Gwendoline Margaret Scholarship B L Butcher Ralph & Ruth Renard Dodgshun - Munz Family Fellowship P F Canobio Jenny Repper - Estate Jeanie McAlpine Robertson - Heartbeat Alfred & Baker Fiona Carmody Kenneth Rich - Estate Kathleen Mary Scholarship Deirdre Carter Otto Richter Cunningham - Joanna Middows Fellowship L G Cheary Patricia Roath - Estate Lieselotte Anna Adeline - - John T Reid Fellowship John & Elsie Cheney Patricia Robertson Brumloop - Dame Elisabeth Murdoch Pamela Christensen William Rooney - Estate Louise Elizabeth Jessie Fellowship Stuart Cohen Peter Ryall Fleming - O’Bryan Family Scholarship Verna Cook J B Ryan - Estate Marion Borrett - Schwartz Family Scholarship Joyce Daws S G & J E Salamy - Estate Marjorie Frances Perry - Ray Shrimpton Memorial M P de Jong Keith J Scott - Estate Merna D Sheahan Travel Award E A & M P Dodd Patricia Singleton - Estate Vernon Charles Burgess All the people listed below are - The Cybec Foundation Scholarship David & Audrey Doig Warren Smith - Estate Violet M Lowe special too. From all of us at the - VEADA Scholarship J D Duffield Ian & Beth Smith - Estate Wilma Ella Dimsey Baker – thank you for your - Ruth Webster Scholarship Heather Eather W J Smith - Estate Jadwiga Maria Bytomski support in 2004. - William Angliss (Vic.) Charitable Louie Margaret Edwards G C Snell Fund M I Euhus C J & E D Soutar Volunteers The Institute is grateful for major - Anonymous K L Fairweather Philip Spry-Bailey AO Robert & Jan Ashe contributions from: Greg J Farmer Jacqueline Stephens Denise Bailey - Atherosclerosis Research Trust Perpetual Scholarships John & Beverley Filgate Harold Stevens RFM Marian Bannister of the UK - Hazel & Pip Appel Fellowship John Franklin Edna Stock Paula Barry - Australian Rotary Health - Bertalli Family Scholarship Fund Maya Friberg Barbara Sutton George & Betty Bird Research Fund - Noel Dickson Scholarship Fund J M Gardiner R & J Taylor Ida Joyce Bourke - Robbie Eisner Scholarship Fund Vincent Gawne - Baker Foundation J L Thompson Elaine Callow - Ruby Wallace Scholarship Fund J M Gibson John Thompson - Juvenile Diabetes Research Bev Cohen - Lang Research Fund Joan Gillespie Stella Thomson Foundation Adrienne Dickson - National Heart Foundation - Edgar Rouse Memorial John & Kathleen Godfrey Ken & Sue Trezise Margot Dixon - National Health & Medical Fellowship Fund James S Guest AM Jennifer Turnbull David & Audrey Doig Research Council - Ethel Mary Baillieu Research Arthur George Hammett J L Vuillemain Jim & Margaret Fairbairn - Victorian Government Scholarship L K Hancock J E Watkins John Harcourt OAM W G Wicks Laurie & Sandra Feldman Baker Research Foundation Baker Gold Club Leslie & Yvonne Harrison Gwen Williams Alan & Flora Fellows (Founding Members) E V Carroll Fred & Susie Hawkins Siew Wong Nita Fone - GSA Group Pty Ltd John Shalit Ida L Hicks Kenneth Woolfe Joyce Fuller - Mr William P Gurry AO Stephen J Cook A David Hore Vern & Shirley Gilbert - Kodak (Australasia) Pty Ltd Albert & Barbara Edwards Robert Hudson Event Sponsors and Donors Jan Goodwin - Mr Norman J O’Bryan K Eisner Frank & Jill Jones AstraZeneca Ron Hancock - Mrs Margaret S Ross Eric & Noelle Garner Gwenda Jones Baker’s Delight Prahran John Harcourt Helen Delamain Glascodine Victor Kalff Barkala Ridge Vineyard Heather Heath Major Donors Richard & Fella Harbig Rob Kerr Booroola Winery Lyall & Betty Jarman - Casella Wines Malcolm Kemp E E Lamburd Brian Chalmers Leask Lindsay & June Jenkins - Elisabeth Murdoch Trust Frank A Roberts John Leslie Casella Wines Philip & Dawn Keast - Gandel Charitable Trust Bernie & Rosemary Robertson Colleen Lewis Chanter’s Ridge Winery Fred & Kathleen Kidd - A S Leslie Eric & June Ross John & Rosemary Lill Cheviot Bridge Vineyard Gwen Kieseker - Joanna Middows Pauline Speedy & Jennifer Tatchell Bill & Betty Ling Chinatique Christine King - Langham Hotels International And 2 Anonymous members Clarissa Linton-Smith Christ Church SouthYarra June Lawrence - Miller Foundation Margery Little Delatite Winery Han-Shin Lee Baker Silver Club John Macdonald - Reece Australia Limited De Giorgio Family Wines Bill & Betty Ling Geoff Bade Joy A Macdonald - BBS & Rosemary Robertson Earl’s Ridge Vineyard Jill Louden Martin P Bade Howard Macmillan - Snowy Nominees Harvey Publicity Enda Markey - Brian & Edwina Watson Lionel & Elaine Berkowitz Phyllis Maggs Heathcote Estate Marjorie Marris Alison Bult Julian Marsh MD - Robert & Jan Lyng David Maxwell Josephine Ferrarin Bill & Margaret Matthews Hellenic Cheese Farm Ian Loftus & Lofty Connections Dot McCoy Trusts & Foundations Peg Gillies Dot McCoy Margit Meier - H & L Hecht Trust Jane Gorman Roma Olive McIntyre Langham Hotels International Wanda Nelson - Harold and Cora Brennen J E Grimwade Neil McLaren Majella Wines Coonawarra Benevolent Trust Leslie & Yvonne Harrison G J McPhee Melbourne City Jaguar Lana Newton - Jack Brockhoff Foundation W Keir Donald Michell Mercury Advertising and Design Keith Nicholson - James & Elsie Borrowman Trust P I & J Korner AO Anne Miller Milawar Cheese Company Norm & Kay Nugent - Joe White Bequest Stephen & Margaret Marks John Dewar Milne Mirvac Properties Margaret O’Brien - L E W Carty Charitable Fund D I McCullough Mary Minogue Moorooduc Estate Patricia O’Shaughnessy - Marian & E H Flack Trust Robert G Miller D Bruce Moore Mt Charlie Winery Joy Parker - Rebecca L Cooper Med Ronald G Pitcher Frederick Moore Murrindindi Vineyards Lorraine Ratcliffe Research Foundation Denzil Smith F R D Morgan CBE Noone Imagewear Heather Rolls - The Danks Trust C Y Sullivan Gweny Mueller Octane Espresso Patricia Singleton

www.baker.edu.au 27 STAFF

Director Career Development Fellows Visiting Scientists Professor Garry Jennings AM - MD, MBBS, FRCP, Dr Terri Allen Dr Melinda Parnell - University of Otago Med FRACP, FAHA Dr Stephen Duffy School, New Zealand Dr Gavin Lambert Associate Directors Dr Rebecca Ritchie Students Professor Mark Cooper - MBBS, FRACP, PhD, Karin Jandeleit-Dahm Paul Gould - PhD (Monash) FAHA, FASN Ruchi Patel - PhD Professor Murray Esler - BMedSci, MBBS, FAAS, PhD SCIENTIFIC DIVISIONS Christine Goh - Honours Justin Mariani - PhD (Monash) Associate Directors ABMU Translational Proteomics Lab - Head Greta Meredith - Honours Professor Alexander Bobik - Bpharm, MSc, PhD Gregory Rice - Phd, Grad Dip Management, Helen Rancie - Honours Professor Anthony Dart - BA, Dphil, BMBCh, FRCP Master Health Administration Cardiac Surgical Research Laboratory Division Heads Professional & Technical staff Head - Myocardial Metabolism Research Professor Mark Cooper - MBBS, FRACP, PhD, Karen Oliva - Dip App Sci Salvatore Pepe - PhD, BSc (Hons), PGrad Dip FAHA, FASN Health Counsel Professor Murray Esler - BMedSci, MBBS, PhD Visiting Scientists Professor David Kaye - MBBS, PhD, FRACP, FACC Clyde Riley - The Royal Women’s Hospital Senior Scientific Nuzhat Ahmed - The Royal Women’s Hospital Alicia Calderone - BbiomedSc (Hons) SENIOR FACULTY Marhta Lappas - Mercy Hospital for Women Rachel Denver - BSc (Hons) (until June 30, 2004) Christine Egan - DipAppScVet Senior Principal Research Fellows Admin Staff Jee-Yoong Leong - MBBS, FRACS Professor Alexander Bobik - Bpharm, MSc, PhD Judi Herschell - Research Awareness and Silvana Marasco - MBBS, MSurg, FRACS Professor Mark Cooper - MBBS, FRACP, PhD, Education Leader Takahiro Oto - MD, PhD FAHA, FASN Deahne Quick - BSc (Hons) Professor Anthony Dart - BA, Dphil, BMBCh, FRCP Clive and Vera Ramaciotti Centre Juliana van der Merwe - BNursing, RN, MPhil Professor Murray Esler - BMedSci, MBBS, PhD for Proteomics and Genomics (from November 2004) Professor Colin I Johnston AO - MBBS, MD (Hon), Proteomics Lab - Head FRACP, FAHA Gert Talbo - PhD Head - Clinical Research Professor Paul J Nestel AO- MD, FTSE, FRACP, FAHA Franklin L Rosenfeldt - MBBS, MD, FRCSE, FRACS Scientific Staff See also page 31 for collaborating surgeons Principal Research Fellows Mustafa Ayhan - PhD Associate Professor Geoffrey Head - BSc (Hons), PhD Visiting Scientists Associate Professor Zygmunt Krozowski - BSc Professional & Technical staff Lea M. Delbridge - PhD, Associate Professor, (Hon), PhD Vincent Strangis - BSc (Hons) Dept Physiology, Melbourne University Associate Professor Elizabeth Woodcock - BSc Lloyd Einsiedel - MBBS, PhD, Macfarlane Burnett (Hons), PhD Cardiology Division Institute for Medical Research Head Takahiro Oto - MD, PhD, Okayama University, Honorary Professors Professor David M Kaye - MBBS, PhD, Japan Dr Peter Little - B Pharm, M Sc, Ph D, ASIA FRACP, FACC Dr Franklin L Rosenfeldt - MBBS, MD, FRCSE, FRACS Students Administrative Freya Sheeran - PhD student NHMRC Fellows Kate Knight - Personal Assistant Olivier van den Brink - PhD student Dr Xiao-Jun Du Jee-Yoong Leong - MS student Dr Jaye Chin-Dusting Wynn Department of Metabolic Cardiology Wendy Ip - Honours student Professor Mark Cooper Head of Department Professor Anthony Dart David M Kaye - MBBS, PhD, FRACP, FACC Cellular Biochemistry Laboratory Professor Murray Esler Head Associate Professor Geoff Head Senior Scientific Staff Elizabeth A Woodcock - BSc (Hons), PhD Professor David Kaye Rebecca Ritchie - BSc (Hons), PhD Dr Bronwyn Kingwell Nagesh Anavekar - MBBS, FRACP Senior Scientific Staff Associate Professor Zyg Krozowski Wei-Zheng Zhang - MSc, PhD Lynne Turnbull - BSc (Hons), PhD Dr Dmitri Sviridov Zhiyong Yang - BSc, MSc, PhD Dr Walter Thomas Professional & Technical Staff Associate Professor Elizabeth Woodcock Professional & Technical Staff Bronwyn Kenney - Dip BiolSc Samara Finch - BSc (Hons) Huy Huynh - BApplSciBiotech JDRF Fellows Tanneale Marshall - BSc (Hons) Dr Josephine Forbes Belinda Smirk - BscMedSci (Hons) Students Dr Zemin Cao Anh Cao - BSc (Hons) Tam Pham - MSc, (Monash University) Claire Gollogly - RN, BSc Oliver Vasilevski - PhD (Swinburne University Carla Enriquez - BSc (Hons) of Technology)

28 Experimental Cardiology Laboratory Visiting Scientists Professional & Technical Heads Genevieve Escher - PhD, Berne Switzerland Jeanette Bourke Xiao-Jun Du - MBBS, M Med, PhD Celia Brenchly - B App Sci (Psychology) Anthony M Dart - BA, BMBCh, Dphil, FRACP Students Nina Eikelis - BSc (Hon) Sally Penfold - Honours (La Trobe) Ling Guo - MD Senior Scientific Elodie Hotchkin - BSc (Hons) Helen Kiriazis - BSc (Hons), PhD Applied Cardiovascular Research Flora Socratous - BSc Shirley Moore - MBBS, Grad Dip Med Sc, PhD Head Xiao-Ming Gao - MBBS, MD, MUNZ Fellowship John Power - BVSc (Hons), PhD Visiting Scientists Qi Xu - MBBS, PhD Klemens Fellner - PhD, Faculty of Mathematics, Professional & Technical Staff University of Vienna, Austria Professional and Technical Adam Bilney - BE (Hons) Yidan Su - MBBS, PhD Francis Fitzpatrick Students Paul Horton Jake Anderson - Honours (Monash) Visiting Scientists Anka Smolic - BScHons, B.App.Sc David Barton - MBBS Aisling McMahon - PhD, Research Fellow, Tye Dawood - PhD (Monash) Victor Chang Cardiac Research Institute, Sydney Students Ishtiaq M Ahmed - MBBS, Research Fellow, Justin Mariani - PhD (Monash) Neuropharmacology Laboratory Victor Chang Cardiac Research Institute, Sydney Head Jie Niu - Beijing, P R China Human Epigenetics Geoffrey A Head - BSc (Hons), PhD Head Students Assam El-Osta - BSc (Hons), PhD Senior Scientific Karen Fang - PhD Melbourne University Dmitry N Mayorov - BSc (Hons), PhD Edna Bajunaki - PhD Melbourne University Staff Geoffrey Wong - Advanced Medical Science, Emma K Baker - PhD Professional & Technical Melbourne University Harikrishnan KN - MSc, PhD Sandra L Burke - BSc (Hons), MSc Kemble Wang - Advanced Medical Science, Sahar Bassal - PhD Luisa La Greca - BBiol Sci (Hons) Melbourne University Chenyi Lo - Advanced Medical Science, Students Visiting Scientists Melbourne University Daniella Brasacchio - PhD (Monash) Dr Elena V Lukoshkova - National Cardiology Maggie Chow - PhD (Melbourne) Research Center, Moscow, Russia Molecular Endocrinology Laboratory Lisa Chang - MBS (Monash) Head Stanley MH Chan - PhD (RMIT) Students Walter G Thomas - BSc (Hons), PhD Scott Maxwell - RMIT University Vascular Pharmacology Laboratory Senior Scientific Head Vascular Division Hongwei Qian - PhD (West Virginia) Jaye Chin-Dusting - BSc (Hons), PhD Head Diem Dinh - BSc (Hons), PhD, Peter Doherty Fellow Professor Mark Cooper - MBBS, FRACP, PhD, Senior Scientific FAHA, FASN Professional & Technical Kevin Woollard - PhD Thao Pham Cardiovascular Nutrition Laboratory Luisa Pipolo - AssDipAppSc Professional & Technical Support Head Ann-Maree Jefferis - BSc Paul Nestel - AO, MD, FTSE, FRACP, FAHA Visiting Scientists Margaret Vincent - AssDipAppSci Angelo D’Amore - PhD Candidate, Emma Jones - BSc (Hons) Senior Scientific Monash University Nora Straznicky - BPharm, PhD, MPH Students Students Nathan Connelly - PhD (Melbourne) Professional & Technical Done Onan - PhD (Monash University) – thesis Ngan Ngoc Huynh - PhD (Monash) Marja Cehun - BEd, RN submitted Rajesh Nair - Masters Prelim (Monash) Nicola Smith - PhD (Melbourne University) Visiting Scientists Hsiu-Wen Chan - PhD (Monash University) Cardiovascular Neuroscience Division Lei Zhang - MD, Peoples Republic of China Cristina Oro - PhD (Monash University) Head Akihiko Fujii - BS, MS Pharmacy, Tohoku University, Enzo Porrello - PhD (Melbourne University) Professor Murray Esler - BMedSci, MBBS, PhD Japan

Molecular Hypertension Laboratory Human Neurotransmitter Laboratory Cell Biology Laboratory Head Head Head Zygmunt Krozowski - PhD Gavin Lambert - PhD Alexander Bobik - BPharm, MSc, PhD

Senior Scientific Senior Scientific Senior Scientific Zhonglin Chai - PhD Marlies Alvarenga - PhD Alex Agrotis - BSc (Hons), PhD Deepak Haikerwal - MBBS, PhD Professional and Technical Staff Jacqueline Hastings - BSc, PhD Professional & Technical Varuni Obeyesekere - BSc (Hons) Elisabeth Lambert - PhD Peter Kanellakis - BSc Michelle Cinel - Cert Vet Nursing, AssDipAppSci Kazuko Masuo - MD, PhD Gina Kostolias - BSc (Hons) (Animal Tech) Glen Wiesner - PhD Giovanna DiVitto - BSc (Hons)

www.baker.edu.au 29 Visiting Scientists Kwee K Seah - AMS (Melbourne) Assoc Directors Natalia Kalinina - PhD, Institute of Experimental Merlin Thomas - PhD (Melbourne) Anthony Dart - BA, DPhil, BMBCh, FRCP Cardiology, Cardiology Research Centre, Moscow, David Chung Kiet Tong - AMS (Melbourne) Murray Esler - BmedSci, MBBS, PhD Russia Louis Teo Loon Yee - AMS (Melbourne) Alexander Bobik - Bpharm, MSc, PhD

Students Clinical Physiology Laboratory Chief Investigators Tina Raj - Honours (Monash) Head Garry Jennings - MD, MBBS, FRCP, FRACP, FAHA Michael Ditiatkovski - PhD (Monash) Bronwyn Kingwell - BSc (Hons), PhD Christopher Reid - BA, DipEd, MSc, PhD Kelly To - PhD (Monash) Murray Esler - BmedSci, MBBS, PhD Senior Scientific David M Kaye - MBBS, PhD, FRACP, FACC Cell Biology of Diabetes Laboratory Barbora de Courten - MD PhD (Senior Bronwyn Kingwell - BSc (Hons), PhD Head Research Officer) Jaye Chin-Dusting - BSc (Hons), PhD Peter J Little - B Pharm, M Sc, Ph D, ASIA Anthony Dart - BA, DPhil, BMBCh, MRCP, FRCP Professional & Technical Staff Professional & Technical Melissa Formosa - BSc Senior Scientific James Cameron - BEElec (Hons), MengSc, MBBS, Melanie Ivey - B Appl Sci Alaina Natoli - BSc(Hons) CPEBiomed Karen Frontanilla - B Appl Sci (Pharm Sci 3rd year) Brian Drew - BSc (Hons) (0.2 EFT) Stephen Duffy - MD, BSc (Hons), PhD, FRACP, Ying Fu - MSc (0.5 EFT) Danielle Alberti Memorial Centre for MRCP, DipRACOG Christoph Gatzka - MD Diabetes Complications (JDRF – Melbourne) Students Jane Thompson - MD, MBBS Head Graduated 2004 Laurence Schneider - MBBS Mark E Cooper - MB BS, PhD, FRACP Christopher Tefft - BSc(Hons) (Monash) Professional & Technical Administrative Current students Laurel Ring Elizabeth Dewar - BSc Anthony White - MBBS PhD (Monash) Sally Kay - SRN, BBm Anna Ahimastos - BBiomedSc(Hons) PhD Monash Senior Scientific Jenny Starr Darren Henstridge - BSc(Hons) PhD (Monash) Jane McPherson Terri Allen - BSc, PhD Brian Drew - BSc(Hons) PhD (Monash) Donna Vizi - Nurse Zemin Cao - MB BS, MD Josephine Forbes - BSc, PhD Lipoproteins and Atherosclerosis Laboratory Visiting Scientists Karin Jandeleit-Dahm - MD, PhD Head Dr Jie Niu - MD, PhD (Beijing University) Phillip Kantharidis - BSc (Hons), PhD Dmitri Sviridov - BSc (Hons), MBBS, FAHA, PhD Alfred & Baker Gene Bank Scientific Professional & Technical Staff Melinda Coughlan - BSc (Hons), PhD Anh Hoang - BSc (Hons) Bernadette Chiodi Philip Koh - BSc (Hons), PhD Ying Fu - MSc Belinda Davis - BSc (Hons), PhD Genevieve Escher - PhD Cardiovascular Disease Prevention Unit Chris Tikellis - BSc (Hons), PhD Urbain Tchoua - PhD Head David Long - BSc (Hons) Monica Robotin - MBBS, FRACS, M Appl Epid, Vicki Thallas - BAppSci Visiting Scientists MBA, M Int Health Craig Smith - BSc (Hons) Michael Bukrinsky - MD, PhD, George Washington Josefa Pete - BSc (Hons) University, Washington DC, USA Katarzyna Bialkowski - BSc (Hons) Senior Scientific Christopher Reid - BA, DipEd, MSc, PhD Professional & Technical Students Maryann Arnstein Chris Tefft - BScHons (Monash) Amy Gatt - BscHons (Deakin) Professional and Technical Wendy Cao Anne Bruce - SRN Gavin Langmaid Kathryn Murphy - SRN Human Vascular Biology Laboratory Sandra Miljavec Ann Nadonza - B Sc Head DipApplSci Claudia Retegan - Dip Sc, BA Stephen Duffy - MB, BS (Hons), PhD, FRACP, MRCP Sheree Purcell Jessele Vinluan - BA Professional & Technical Visiting Scientists Students Lovisa Dousha - BSc (Hons) Markus Lassila - BSc, Msc, PhD, Finland Jessica Chellappah - PhD (Monash) Geoffrey Boner - MB ChB, South Africa Mehernaz Sadafi - Pharmaceutical Sciences (RMIT) Guorong Ma - MD, Nephrology, China Students Xiao Li Zhang - MD, Endocrinology, China Swati Mukherjee - PhD (Monash) Risk Reduction Clinic Kei Fukami - MD, Nephrology, Japan Darren Henstridge - PhD (Monash) Nurses Janis Jennings - SRN Students Alfred Baker Medical Unit - NHMRC Virginia Cable - SRN Vishal Boolell - AMS (Melbourne) Centre for Clinical Research Excellence Elizabeth Jenkins - SRN Wendy Burns - PhD (Melbourne) Head Marijke Tress Anna Calkin - PhD (Monash) Garry Jennings - MD, MBBS, FRCP, FRACP, FAHA Di Wilson Brooke Harcourt - BSc, Hons (Monash) Yen Pham - Honours (Monash) Deputy Director Administration Georgia Soldatos - PhD (Monash) David M Kaye - MBBS, PhD, FRACP, FACC Amanda Coats - BA

30 Core Facilities Marketing and Fundraising Animal Ethics Committee Clive and Vera Ramaciotti Centre for Kristen Boschma - Head Marketing & David Anderson (Acting Chair) Proteomic and Genomic Research Communication, BBus, AMFIA, AIMM Carol Bear Greg Rice Bobbie Renard - Manager Community Relations, MFIA Lynda Bonning Trish Roath - Fundraising Manager, MFIA Roy Burrows Adenoviral Gene delivery Gene Sequencing Elizabeth Veal - Fundraising Projects Manager, MFIA Paul Dover Walter G Thomas Viv Talbot - Donor Liaison & Planned Giving Officer Lindsay Herbert Brooke Keast - Marketing & Event Coordinator, Patricia Keith Morphology BComn Helen Kiriazis Mouse Physiology Kylie Nelson - Database & Donor Liaison Officer Denise Noonan Xiao-Jun Du Leonie Poulter Building Infrastructure Management Deb Ramsey Clinical Trials Steve Droste - Building Infrastructure Manager BEng Rachel Spiby Christopher Reid Carole Webb Biomedical Engineering David Spiteri Clinical Research Laboratories Philip Carruthers-Bleasdale - Electronic Engineer Anthony Dart Scholars Executive Committee Operations Jaye Chin-Dusting Precinct Animal Centre Simon Neil - Scientific Projects Officer, MSc Rodney Dilley Debra Ramsey Valerie Saunders - Personal Assistant to the Murray Esler Phillip Kantharidis David Spiteri Director, BSSc Cathy LeMoignan Rebecca Lew Imaging Applications Department Precinct Animal Centre Bobbie Renard AMREP Library & Education Centre Debra Ramsey - Animal Services Manager, Walter Thomas (Chair) Adam Clark AppSc (Animal Tech) BHIT Viccy Wootton Susan Mooney - Operations Manager Operational, Administrative & Support Staff David Spiteri - Operations Manager, Equipment Committee Chief Operating Officer AppSc (Animal Tech) WMCT Anita Furnell Erica Hughes - BA, ASIA Kylie Aquilina - Technical Assistant Production, Assam El-Osta AppSc (Animal Tech) VUT Elizabeth Dewar Finance and Administration Josephine Balzan - Support Technical Assistant Geoff Head Anita Furnell - Director, BComm, ACA Experimental, AppSc (Animal Tech) BHIT Patricia Roath Ronald Mak - Senior Accountant, BBS, CA, MIMS Claire Doran - Technical assistant, Phillip Kantharidis (Chair) Gary Loetsch - Accountant, BEc (Acc), CPA, DipOD App Sci(Animal Tech) BHIT Simon Vergers Helen Green - Finance Officer Rhianna Hoyle - Experimental Services Steve Droste Ally Noble - Payroll Officer Technical Assistant Zygmunt Krozowski Sharon Kalbstein - Receptionist Samantha Hulme - Experimental Services Technical Assistant, AppSc (Animal Tech) Grants Committee Commercialisation Mia Ibrahim - Technical Assistant Tony Dart Tina Rankovitch - Head of Commercialisation, Fiona Keurentjes - Technical Assistant, Assam El-Osta DipDiagRad, GradDipMgmt, AIMM, AMAMI AppSc (Animal Tech) Anita Furnell (to Dec 04) Kirsty Lee - Technical Assistant Heather Gallichio Rajani Jasti - Admin officer, MSC (Animal Sci) Geoff Head Julia Hill - Head of Commercialisation, BSc (Hons), Hayley Aisbett - Technical Assistant Colin Johnston (Chair) PhD, MBA (Current) Xin Du - Technical Assistant Peta McLaughlin Laura Beaumont - Theatre/Animal Technician, Greg Rice Human Resources DipAppSc (Animal Technology) Walter Thomas Barbara Kaye - Human Resources Manager John Crawford - Technical Assistant PAC Elizabeth Woodcock Kylie McNair - Human Resources Officer Lynda Bonning - Veterinarian, BVSc Hons Kenny Scicluna - Technical Assistant PAC Associates Occupational Health & Safety Michelle Kirk - Technical Assistant PAC Alfred Hospital Colleagues Tracey Oakes - Project Officer, B Applied Sc Cardiac Surgery (Nursing), SRN, Grad Dip OHS Management Committees Donald Esmore Noel Tresider - Chemical Project Officer, Assoc. Dip International Scientific Advisory Board 2004 Jee-Yoong Leong Chem, Assoc Dip Chem Eng, CIH Ralph Bradshaw - Department of Physiology Silvana Marasco & Biophysics, College of Medicine, University of Justin Negri Information Services Group California, USA Michael Rowland Ian Briggs - Information Technology Manager Robert Salamonsen Damian Lee - Support Officer Ken Chien - UCSD Institute of Molecular Medicine, James Anderson University of California, USA Kate Kingsford-Smith Imaging Applications Robyn McEgan Alan Hibbs Gianni Gromo - Head, Discovery Research, Mark Mennen F Hoffman-La Roche, Basel, Switzerland Arthur Preovolos

www.baker.edu.au 31 FINANCIAL REPORT

BAKER MEDICAL RESEARCH INSTITUTE Statement of Financial Performance for the year ended 31 December 2004

2004 2003 $$

Revenue from ordinary activities 21,665,415 22,462,778

Expenses for building works (1,895,018) (3,958,932) Employee benefits expense (12,151,775) (11,668,728) Laboratory consumables (3,380,071) (2,472,703) Depreciation and amortisation expenses (1,179,143) (1,278,636) Building overheads (621,616) (869,282) Borrowing costs expense (35,552) (64,171) Laboratory support expenses (1,000,458) (1,659,138) Other expenses from ordinary activities (1,536,463) (992,443)

Deficit from ordinary activities before income tax expense (134,681) (501,255)

Income tax expense - -

Deficit from ordinary activities after income tax expense (134,681) (501,255)

Net profit attributable to outside equity interest 50,019 309,642

Total changes in funds (84,662) (191,613)

32 BAKER MEDICAL RESEARCH INSTITUTE Statement of Financial Position as at 31 December 2004

2004 2003 $$ ASSETS Current assets Cash assets 2,743,367 5,250,339 Receivables 3,098,570 2,558,073 Other 90,753 136,204

Total current assets 5,932,690 7,944,616

Non-current assets Investments accounted for using the equity method 381,459 331,440 Investments 6,901,515 3,239,535 Plant & equipment 4,513,798 4,551,523

Total non-current assets 11,796,772 8,122,498

TOTAL ASSETS 17,729,462 16,067,114

LIABILITIES Current liabilities Interest bearing liabilities - 292,897 Payables 4,169,277 2,303,567 Prepaid grants 1,661,852 1,361,390 Provisions 1,727,578 1,752,963

Total current liabilities 7,558,707 5,710,817

Non-current liabilities Interest bearing liabilities - 84,334 Provisions 241,123 257,669

Total non-current liabilities 241,123 342,003

TOTAL LIABILITIES 7,799,830 6,052,820

NET ASSETS 9,929,632 10,014,294

FUNDS Accumulated funds Operating fund (8,958,011) (9,013,751) Capital fund 17,969,865 18,159,608 Specific purpose fund 536,319 536,997

TOTAL BAKER FUNDS 9,548,173 9,682,854

Outside equity interest 381,459 331,440

TOTAL FUNDS 9,929,632 10,014,294

www.baker.edu.au 33 BAKER MEDICAL RESEARCH INSTITUTE Statement of Cash Flows for the year ended 31 December 2004

2004 2003 $$

Cash flows from ordinary activities Receipts from granting bodies 9,193,008 10,946,558 Donations, bequests and commercial activities 9,844,572 9,262,642 Receipts for building works 450,000 460,000 Payments to suppliers & employees (inclusive of goods and services tax) (18,769,539) (20,072,337) Dividends received 288,629 327,279 Interest received 191,645 1,003,311 Rent received - Baker building 417,988 483,357 General income 89,269 430,539 Borrowing costs (35,552) (64,171)

Net cash inflow from ordinary activities 2,255,343 2,191,855

Cash flows from investing activities Payment for investment securities (5,856,551) (1,425,302) Proceeds from sale of investment securities 2,575,918 5,883,740 Payment for property, plant & equipment (1,264,789) (1,009,580) Proceeds from sale of property, plant & equipment - 80,735

Net cash outflow from investing activities (4,545,422) 3,529,593

Cash flows from financing activities Principal repayments under finance leases - (30,509)

Net cash outflow from financing activities - (30,509)

Net cash increase in cash held (2,290,079) 5,690,939

Cash at beginning of the financial year 4,998,710 (672,509) Effects of exchange rate changes on cash held in foreign currencies 34,736 (19,720)

Cash at the end of the financial year 2,743,367 4,998,710

The summary financial information provided above and in the preceding two pages, being a statement of financial performance, statement of financial position and statement of cash flows, has been extracted from the audited financial statements of the Baker Medical Research Institute. The summary financial information does not include all the information and notes normally included in a statutory set of financial statements. A full set of statutory financial statements can be obtained from our website at http://www.baker.edu.au.

The statutory financial statements (from which the summary financial information has been extracted) have been prepared in accordance with generally accepted accounting principles in Australia and relevant Australian accounting standards. The statutory financial statements were qualified by the auditors in respect to the Institute’s policy to expense capital works undertaken on the buildings which the Institute utilises. Full details of the audit qualification are contained in the statutory financial statements.

34 PUBLICATIONS

Journal Articles restricted expression in cell types associated with growth, Clifton PM, Noakes M, Sullivan D, Erichsen N, Ross D, Agrotis A, Kanellakis P, Kostolias G, Di Vitto G, Wei C, calcium exchange and homeostasis. Exp Cell Res Annison G, Fassoulakis Hannan R, Jennings G, Bobik A. Proliferation of neointimal 2004;293:31-42. smooth muscle cells after arterial injury: Dependency on Chronopoulos A, Cehun M, Nestel P. Cholesterol-lowering interactions between fibroblast growth factor receptor-2 Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a effects of plant sterol esters differ in milk, yoghurt, bread and fibroblast growth factor-9. J Biol Chem new regulator of the renin-angiotensin system. Trends and cereal. Eur J Clin Nutr 2004;58:503-9. 2004;279:42221-9. Endocrinol Metab 2004;15:166-9. Cole TJ, Solomon NM, Van Driel R, Monk JA, Bird D, Ahlers BA, Parnell MM, Chin-Dusting JP, Kaye DM. An Byrne MJ, Kaye DM, Mathis M, Reuter DG, Alferness CA, Richardson SJ, Dilley RJ, Hooper SB. Altered epithelial cell age-related decline in endothelial function is not Power JM. Percutaneous mitral annular reduction provides proportions in the fetal lung of glucocorticoid receptor associated with alterations in L-arginine transport in continued benefit in an ovine model of dilated null mice. Am J Respir Cell Mol Biol 2004;30:613-9. humans. J Hypertens 2004;22:321-7. cardiomyopathy. Circulation 2004;110:3088-92. Cooper M, Boner G. Dual blockade of the renin- Allen TJ, Cooper ME, Lan HY. Use of genetic mouse Cameron JD, Stevenson I, Reed E, McGrath BP, Dart AM, angiotensin system in diabetic nephropathy. Diabet Med models in the study of diabetic nephropathy. Curr Ather Kingwell BA. Accuracy of automated auscultatory blood 2004;21:15-8. Rep 2004;6:197-202 pressure measurement during supine exercise and treadmill stress electrocardiogram-testing. Cooper ME. Gastrointestinal function in diabetes mellitus. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse Blood Press Monit 2004;9:269-75. Intern Med J 2004;34:659. models in the study of diabetic nephropathy. Curr Diab Rep 2004;4:435-40. Camm EJ, Harding R, Lambert GW, Gibbs ME. The role of Cooper ME. Importance of advanced glycation end catecholamines in memory impairment in chicks following products in diabetes-associated cardiovascular and renal Anderson R, Dart AM, Starr J, Shaw J, Chin-Dusting JP. reduced gas exchange in ovo. Neuroscience disease. Am J Hypertens 2004;17(12 Pt 2):31S-38S. Plasma C-reactive protein, but not protein S, VCAM-1, von 2004;128:545-53. Willebrand factor or P-selectin, is associated with Coughlan MT, Permezel M, Georgiou HM, Rice GE. endothelium dysfunction in coronary artery disease. Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence Repression of oxidant-induced nuclear factor-kappaB Atherosclerosis 2004;172:345-51. against a major role for angiotension converting enzyme- activity mediates placental cytokine responses in related carboxypeptidase (ACE2) in angiotensin peptide gestational diabetes. J Clin Endocrinol Metab Angus PW, Vaughan RB, Chin-Dusting JP. Responses to metabolism in the human coronary circulation. J 2004;89:3585-94. endothelin-1 in-patients with advanced cirrhosis before Hypertens 2004;22:1971-76. and after liver transplantation. Gut 2004;53:773. Coughlan MT,Vervaart PP, Permezel M, Georgiou HM, Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper Rice GE. Altered placental oxidative stress status in Baker EK, El-Osta A. MDR1, Chemotherapy and Chromatin ME, Jandeleit-Dahm KA. Irbesartan but not amlodipine gestational diabetes mellitus. Placenta 2004;25:78-84. Remodeling. Cancer Biol Ther 2004;3:819-24. suppresses diabetes-associated atherosclerosis. Circulation 2004;109:1536-42. Dart AM, Gatzka CD, Cameron JD, Kingwell BA, Liang YL, Ballinger ML, Nigro J, Frontanilla KV, Dart AM, Little PJ. Berry KL, Reid CM, Jennings GL. Large artery stiffness is not Regulation of glycosaminoglycan structure and Cao Z, Li Y.The chemical inducibility of mouse cardiac related to plasma cholesterol in older subjects with atherogenesis. Cell Mol Life Sci 2004;61:1296-306. antioxidants and phase 2 enzymes in vivo. Biochem hypertension. Arterioscler Thromb Vasc Biol 2004;24:962-68. Biophys Res Commun 2004;14:1080-8. Barton DA, Dawood T, Lambert GW. Depression and its Davis B, Forbes JM, Thomas MC, Jerums G, Burns WC, impact on heart disease development and prognosis. Cao Z, Li Y. Potent inhibition of peroxynitrite-induced DNA Kawachi H, Allen TJ, Cooper ME. Superior renoprotective Directions in Psychiatry 2004;24:81-8. strand breakage by ethanol: possible implications for effects of combination therapy with ACE and AGE ethanol-mediated cardiovascular protection. Pharmacol inhibition in the diabetic spontaneously hypertensive rat. Berardi P, Russell M, El-Osta A, Riabowol K. Functional Res 2004;50:13-9. Diabetologia 2004;47:89-97. links between transcription, DNA repair and apoptosis. Cell Mol Life Sci 2004;61:2173-80. Chan JC, Wat NM, So WY, Lam KS, Chua CT,Wong KS, De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Snapinn, S, Cooper ME, Mitch WE, Brenner Berry KL, Cameron JD, Dart AM, Dewar EM, Gatzka CD, Shahinfar S, Brenner BM, Kurokawa K; Reduction In BM. Albuminuria, a therapeutic target for cardiovascular Jennings GL, Liang YL, Reid CM, Kingwell BA. Large artery Endpoints in NIDDM with Angiotensin II Antagonist protection in type 2 diabetic patients with nephropathy. stiffness contributes to the greater prevalence of systolic Lostartan Study Investigators. Renin angiotensin Circulation 2004;110:921-7. hypertension in elderly women. J Am Geriatr Soc aldosterone system blockade and renal disease in patients 2004;52:368-73. with type 2 diabetes: an Asian perspective from the De Zeeuw, Remuzzi G, Parving HH, Keane WF, Zhang Z, RENAAL study. Diabetes Care 2004;27:874-9. Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner Boak L, Chin-Dusting JPF. Hypercholesterolemia BM. Proteinuria, a target for renoprotection in patients and endothelium dysfunction: role of dietary Chin-Dusting JP, Boak L, Husband A, Nestel PJ. The with type 2 diabetic nephropathy: lessons from RENAAL. supplementation as vascular protective agents. isoflavone metabolite dehydroequol produces Kidney Int 2004;65:2309-20. Curr Vasc Pharmacol 2004; 2:45-52. vasodilatation in human resistance arteries via a nitric oxide-dependent mechanism. Atherosclerosis Dilley RJ. A novel inhibitory role for CREG-mediated Bobik A. Aspirin, superoxide anions and development of 2004;176:45-8. signalling in cardiac hypertrophy. J Hypertens hypertension. J Hypertens 2004;22:681-2. 2004;22:1469-71. Chin-Dusting JPF, Rasaratnam B, Kaye DM, Jennings G Bobik A. Hypertension, transforming growth factor-beta, and Dudley F. Can de-bugging the system prevent Dilley RJ, Rizkalla B, Bertram JF. Cardiovascular angiotensin II and kidney disease. J Hypertens complications of cirrhosis? The answer may be NO. hypertrophy in one-kidney, one-clip renal hypertension is 2004;22:1265-7. Gastroenterology 2004;126:928. Author’s reply. resistant to heparin. J Hypertens 2004;22:767-74.

Boesen EI, Lambert GW, Anderson WP, Kett MM. Pre- Clifton PM, Noakes M, Ross D, Fassoulakis A, Cehun M, Dinh DT, Qian H, Seeber R, Lim E, Pfleger K, Eidne KA, weaning carvedilol treatment attenuates hypertension Nestel P. High dietary intake of phytosterol esters Thomas WG. Helix I of {beta}-arrestin is involved in post- development in SHR. Eur J Pharmacol 2004;486:183-8. decreases carotenoids and increases plasma plant sterol endocytic trafficking, but is not required for membrane Brasier G, Tikellis C, Xuereb L, Craigie J, Casley D, Kovacs levels with no additional cholesterol lowering. J Lipid Res translocation, receptor binding and internalization. Mol CS, Fudge NJ, Kalnins R, Cooper ME, Wookey PJ. Novel 2004;45:1493-9. Pharmacol 2004;67:375-82. hexad repeats conserved in a putative transporter with

www.baker.edu.au 35 Douglas GC, O’Bryan MK, Hedger MP, Lee DK, Yarski MA, Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein Smith AI, Lew RA. The novel angiotensin-converting ME. The effects of valsartan on the accumulation of KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, enzyme (ACE) homolog, ACE2, is selectively expressed by circulating and renal advanced glycation end products in Sollott SJ. Glycogen synthase kinase-3beta mediates adult Leydig cells of the testis. Endocrinology experimental diabetes. Kidney Int Suppl 2004;92:5.302. convergence of protection signaling to inhibit the 2004;145:4703-11. mitochondrial permeability transition pore. J Clin Invest Forbes JM, Yee LT,Thallas V, Lassila M, Candido R, 2004;113:1526-8. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Kingwell BA. High density lipoprotein and Apolipoprotein Thorpe SM, Cooper ME, Allen TJ. Advanced glycation end Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, AI increase eNOS activity via direct protein association product interventions reduce diabetes-accelerated Kostolias G, Ilyinskaya O, Tararak E, Bobik A. Increased and multisite phopshorylation. Proc Natl Acad Sci USA atherosclerosis. Diabetes 2004;53:1813-23. expression of the DNA-binding cytokine HMGB1 in 2004;4:6999-7004. human atherosclerotic lesions: role of activated Forbes JM, Yee LTL, Thallas V, Lassila M, Candido R, macrophages and cytokines. Arterioscler Thromb Vasc Biol Du XJ. Gender modulates cardiac phenotype development Jandeleit-Dahm K, Thomas MC, Burns WC, Deemer E, 2004;24:2320-5. in genetically modified mice. Cardiovasc Res Thorpe SR, Cooper ME, Allen TJ. Role of advanced 2004;63:510-9. glycation end products in diabetes associated Kalinina N, Agrotis A, Antropova Y, Ilyinskaya O, Smirnov V, atherosclerosis. Diabetes 2004;53:1824-30. Tararak E, Bobik A. Smad expression in human Du XJ. Role of extracellular matrix in cardiac atherosclerotic lesions: evidence for impaired TGF- pathophysiology: recent findings from studies using mice. Fu Y, Hoang A, Escher G, Parton RG, Krozowski Z, Sviridov beta/Smad signaling in smooth muscle cells of fibrofatty Chinese J Pathophysiology 2004;20:2369-71. D. Expression of caveolin-1 enhances cholesterol efflux in lesions. Arterioscler Thromb Vasc Biol 2004;24:1391-6. hepatic cells. J Biol Chem 2004;279:14140-6. Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Kanellakis P, Nestel P, Bobik A. Angioplasty-induced Finch AM, Chaulet H, Graham RM. Genetic enhancement Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y,Takeuchi superoxide anions and neointimal hyperplasia in the of ventricular contractility protects against pressure- M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, rabbit carotid artery: suppression by the isoflavone trans- overload-induced cardiac dysfunction. J Mol Cell Cardiol Cooper ME, Okuda S. AGEs activate mesangial TGF-beta- tetrahydrodaidzein. Atherosclerosis 2004;176:63-72. 2004;37:979-87. Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66:2137-47. Kanellis J, Levidiotis V, Khong T, Cox AJ, Stacker SA, Du XJ, Feng X, Gao XM, Tan TP, Kiriazis H, Dart AM. If Gilbert RE, Cooper E, Power DA. A study of VEGF and its channel inhibitor ivabradine lowers heart rate in mice with Hastings JA, Morris MJ, Lambert G, Lambert E, Esler M. receptors in two rat models of proteinuria. Nephron enhanced sympathoadrenergic activities. Br J Pharmacol NPY and NPY Y1 receptor effects on noradrenaline Physiol 2004;96:26-36. 2004;142:107-12. overflow from the rat brain in vitro. Regul Pept 2004;120:107-12. Kang KB, Wang TT,Woon CT, Cheah ST, Lim YK, Moore XL, Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Wong MC. Celecoxib enhances brain tumor cell Morris M, Hastings J, Socratous F, Esler M. Extra-adipocyte Head GA, Burke SL. Sympathetic responses to stress and radiosensitivity leading to massive tumor necrosis. Ann leptin release in human obesity and its relation to rilmenidine in 2K1C rabbits: evidence of enhanced Acad Med Singapore 2004; Vol 33 (Suppl) 5, S19. sympathoadrenal function. Am J Physiol Endocrinol Metab nonvascular effector mechanism. Hypertension 2004;286:E744-52. 2004;43:636-42. Karagiannis TC, El-Osta A. Epigenetic changes activate widespread signals in response to double-strand breaks. El-Osta A. The rise and fall of genomic methylation in Head GA, Lukoshkova EV, Mayorov DN, van den Buuse M. Cancer Biol Ther 2004;3:617-23. cancer. Leukemia 2004;18:233-7. Non-symmetrical double-logistic analysis of 24-h blood pressure recordings in normotensive and hypertensive Karagiannis TC, El-Osta A. Double-strand breaks: signaling El-Osta A. Understanding the consequences of epigenetic rats. J Hypertens 2004;22:2075-85. pathways and repair mechanisms. Cell Mol Life Sc mechanisms and its effects on transcription in health and 2004;61:2137-47. disease. Cancer Biol Ther 2004;3:816-8. Head GA, Obeyesekere V, Jones ME, Simpson ER, Krozowski ZS. Aromatase-deficient (ArKO) mice have Karagiannis TC, El-Osta A. siRNAs: Mechanism of RNA El-Osta A. Coordination of epigenetic events. Cell Mol Life reduced blood pressure and baroreflex sensitivity. Interference, In Vivo and Potential Clinical Applications. Sci 2004;61:2135-6. Endocrinology 2004;145:4286-91. Cancer Biol Ther 2004;3:1069-74.

Esler M. An explanation of the unexpected efficacy of Head GA, Reid CM, Lukoshkova EV. Non-symmetrical Kaye DM, Mansfield D, Naughton MT. Continuous L-DOPS in pure autonomic failure.Clin Auton Res. double logistic analysis of ambulatory blood pressure positive airway pressure decreases myocardial oxygen 2004;14:356-7. recordings. J Appl Physiol 2004;[Epub ahead of print]. consumption in heart failure. Clin Sci (Lond) 2004;106:599-603. Esler M, Lux A, Hastings J, Socratous F, Lambert G. Headey SJ, Keizer DW, Yao S, Brasier G, Kantharidis P, Rilmenidine sympatholytic activity preserves mental and Bach LA, Norton RS. C-terminal domain of insulin-like Kaye DM, Smirk B, Finch S, Williams C, Esler MD. orthostatic sympathetic response and epinephrine growth factor (IGF) binding protein-6: structure and Interaction between cardiac sympathetic drive and heart secretion. J Hypertens 2004;22:A7-8. interaction with IGF-II. C-terminal domain of insulin-like rate in heart failure: modulation by adrenergic receptor growth factor (IGF) binding protein-6: structure and genotype. J Am Coll Cardiol 2004;16:2008-15. Esler M, Lux A, Jennings G, Hastings J, Socratous F, interaction with IGF-II. Mol Endocrinol 2004;18:2740-50. Lambert G. Rilmenidine sympatholytic activity preserves Kn H, Bassal S, Tikellis C, El-Osta A. Expression Analysis of mental stress, orthostatic sympathetic responses and Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, the Epigenetic Methyltransferases and Methyl-CpG adrenaline secretion. J Hypertens 2004;22:1529-34. Dawood T, Komesaroff PA. Hormone therapy impairs Binding Protein Families in the Normal B-Cell and B-Cell endothelial function in postmenopausal women with type Chronic Lymphocytic Leukemia (CLL). Cancer Biol Ther Esler M, Parati G. Is essential hypertension sometimes a 2 diabetes mellitus treated with rosiglitazone. J Clin 2004;3:[Epub ahead of print]. psychosomatic disorder? J Hypertens 2004;22:873-6. Endocrin Met 2004;89:4615-19. Kockx M, Rye KA, Gaus K, Quinn CM, Wright J, Sloane T, Fang L, Wei HM, Mak KH, Xiong ZW, Song J, Lim YL, Jennings GL. The left atrium in hypertension: next to the Sviridov D, Fu Y, Sullivan D, Burnett JR, Rust S, Assmann G, Chatterjee S. Markers of low-grade inflammation and chamber of power. J Hypertens 2004;22:1473-4. Anantharamaiah GM, Palgunachari MN, Katz SL, Phillips soluble cell adhesion molecules in Chinese patients with MC, Dean RT, Jessup W, Kritharides L. Apolipoprotein A-I- coronary artery disease. Can J Cardiol 2004;20:1433-8. Jennings GL, Kingwell BA. Measuring arterial function in stimulated apolipoprotein E secretion from human diabetes. J Hypertens 2004:22 1863-65 macrophages is independent of cholesterol efflux. J Biol Ferrier KE, Nestel P,Taylor A, Drew BG, Kingwell BA. Diet but Chem 2004;279:25966-77. not aerobic exercise training reduces skeletal muscle TNF- Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, alpha in overweight humans. Diabetologia 2004;47:630-7. Hammond JJ, O’Brien RC, Raffaele J, Tsalamandris C; Kompa AR, Thomas WG, See F,Tzanidis A, Hannan RD, Melbourne Diabetic Nephropathy Study Group. Long-term Krum H. Cardiovascular role of urotensin II: effect of Forbes JM, Thallas-Bonke V, Cooper ME, Thomas MC. renoprotection by perindopril or nifedipine in non- chronic infusion in the rat. Peptides 2004;25:1783-8. Advanced glycation: how are we progressing to combat hypertensive patients with Type 2 diabetes and this web of sugar nomalies in diabetic nephropathy. microalbuminuria. Diabet Med 2004;2004:1192-9. Kule CE, Karoor V, Day JN, Thomas WG, Baker KM, Dinh Curr Pharm Des 2004;10:3361-72. D, Acker KA, Booz GW. Agonist-dependent Johnston C. Hormones and the cardiovascular system. internalization of the angiotensin II type one receptor Trends Endocrinol Metab 2004;15:137-8. (AT1): role of C-terminus phosphorylation in

36 recruitment of beta-arrestins. Regul Pept McCrystal GD, Pepe S, McDonald P. Esmore DS, Rosenfeldt urokinase and tissue-type plasminogen activators on 2004;120:141-8. FL. The challenge of improving donor heart preservation. neointima formation and vessel remodelling after arterial Heart Lung Circ 2004;13:74-83. injury. J Vasc Res 2004;41:286-76. Lambert GA, Hoskin KL, Zagami AS. Nitrergic and glutamatergic neuronal mechanisms at the McGlennan A, Esler M, Stocks G, Pandit V. PFA-100 and Parnell MM, Chin-Dusting JP, Starr J, Kaye DM. In vivo and trigeminovascular first-order synapse. Neuropharmacology regional analgesia in a parturient after ibuprofen in vitro evidence for ACh-stimulated L-arginine uptake. Am 2004;47:92-105. overdose. Br J Anaesth 2004;92:776-7. J Physiol Heart Circ Physiol 2004;287:H395-400.

Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Cross-talk Candido R, Cooper ME. Imatinib attenuates diabetes- Matrix metalloproteinase-9 genotype influences large artery of opioid peptide receptor and beta-adrenergic receptor associated atherosclerosis. Arterioscler Thromb Vasc Biol stiffness through effects on aortic gene and protein signalling in the heart. Cardiovasc Res 2004;63:414-22. 2004;24:935-42. expression. Arterioscler Thromb Vasc Biol 2004;24:1479-84. Pittaway JK, Ahuja KD, Chronopoulos A, , Cehun M, Lassila M, Cooper ME, Jandeleit-Dahm K. Antiproteinuric Mifsud SA, Burrell LM, Kubota E, Jaworski K, Cooper ME, Robertson IK, Nestel PJ, Ball MJ. The effect of chickpeas effect of RAS blockade: new mechanisms. Curr Hypertens Wilkinson-Berka JL. Cardiorenal protective effects of on human serum lipids and lipoproteins. Asia Pac J Clin Rep 2004;6:383-92. vasopeptidase inhibition with omapatrilat in hypertensive Nutr 2004;13:S70. transgenic (mREN-2) rats. Clin Exp Hypertens Lassila M, Seah KK, Allen TJ, Thallas V,Thomas MC, 2004;26:69-80. Power JM, Sah P. Intracellular calcium store filling by an L- Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, type calcium current in the basolateral amygdala at Jandeleit-Dahm KA. Accelerated nephropathy in diabetic Mogensen CE, Cooper ME. Diabetic renal disease: from subthreshold membrane potentials. J Physiol 2004;562(Pt apolipoprotein e-knockout mouse: role of advanced recent studies to improved clinical practice. Diabet Med 2):439-53. glycation end products. J Am Soc Nephrol 2004;21:4-17. 2004;15:2125-38. Rasaratnam B, Connelly N, Chin-Dusting JP. Nitric oxide Moore XL, Lu J, Sun L, Zhu CJ, Tan P,Wong MC. and the hyperdynamic circulation in cirrhosis: Is there a Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Endothelial progenitor cells' “homing” specificity to brain role for selective intestinal decontamination?. Clin Sci Cooper ME, Forbes JM. Interactions between angiotensin tumors. Gene Ther 2004;11:811-8. (Lond) 2004;107:425-34. II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic Morris JB, Pham TM, Kenney B, Sheppard KE, Woodcock Rehn AE, Van Den Buuse M, Copolov D, Briscoe T, Lambert nephropathy. Am Soc Nephrol 2004;15:2139-51. EA. UTP transactivates epidermal growth factor receptors G, Rees S. An animal model of chronic placental and promotes cardiomyocyte hypertrophy despite insufficiency: relevance to neurodevelopmental disorders Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA. inhibiting transcription of the hypertrophic marker gene, including schizophrenia. Neuroscience. 2004;129:381-91. Heparanase is involved in the pathogenesis of proteinuria atrial natriuretic peptide. J Biol Chem 2004;5:8740-6. as a result of glomerulonephritis. J Am Soc Nephrol Reid,CM, Rockell M, Skillington PD, Shardey GC, Smith JA, 2004;15:68-78. Mucha GT, Merkel S, Thomas W, Bantle JP. Fasting and Yii, M, Seevanayagam S, Mohajeri M, Rowland M. Twelve insulin glargine in individuals with type 1 diabetes. months experience and analysis from the Australasian Lew RA. HPLC in the analysis of peptide metabolism. Diabetes Care 2004;27:1209-10. Society of Cardiac and Thoracic Surgeons - Victorian Methods Mol Biol 2004;251:275-90. Database Project. Heart Lung Circ 2004;13:291-7. Naughton MT, Mansfield DR, Kaye DM, Bergin P, Li HJ, Wang W, Huang XR, Oldfield M, Schmidt AM, Richardson M. Heart failure: how can we prevent the Ritchie RH, Rosenkranz AC, Huynh LP, Stephenson T, Kaye Cooper ME, Lan HY.Advanced glycation end products epidemic. Med J Aust 2004;2:143. DM, Dusting GJ. Activation of IP prostanoid receptors induce tubular epithelial-myofibroblast transition through prevents cardiomyocyte hypertrophy via cAMP-dependent the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Nestel P. Metabolic complications of obesity. Asia Pac J signaling. Am J Physiol Heart Circ Physiol Pathol 2004;164:1389-97. Clin Nutr. 2004;13(Suppl):S35. 2004;287:H179-85.

Ling S, Dai A, Dilley RJ, Jones M, Simpson E, Komesaroff Nestel P. Nutritional aspects in the causation and Roebuck T, Solin P, Kaye DM, Bergin P, Bailey M, PA, Sudhir K. Endogenous estrogen deficiency reduces management of the metabolic syndrome. Endocrinol Naughton MT. Increased long-term mortality in heart proliferation and enhances apoptosis-related death in Metab Clin North Am 2004;33:483-92. failure due to sleep apnoea is not yet proven. Eur Respir J vascular smooth muscle cells: insights from the 2004;23:735-40. aromatase-knockout mouse. Circulation 2004;3:537-43. Nestel P, Cehun M, Chronopoulos A. Effects of long-term consumption and single meals of chickpeas on plasma Rosenfeldt F, Miller F, Nagley P, Hadj A, Marasco S, Quick Ling S, Dai A, Williams MR, Husband AJ, Nestel PJ, glucose, insulin, and triacylglycerol concentrations. Am J D, Sheeran F,Wowk M, Pepe S. Response of the senescent Komesaroff PA, Sudhir K. The isoflavone metabolite Clin Nutr 2004;79:390-5. heart to stress: clinical therapeutic strategies and quest cis-tetrahydrodaidzein inhibits ERK-1 activation and for mitochondrial predictors of biological age. Ann N Y proliferation in human vascular smooth muscle cells. Nestel P, Cehun M, Chronopoulos A. A biochanin-enriched Acad Sci 2004;1019:78-84. J Cardiovasc Pharmacol 2004;43:622-8. isoflavone from red clover lowers LDL cholesterol in men Eur J Clin Nutr. Am J Clin Nutr 2004;58:403-8. Rubis B, Grodecka-Gazdecka S, Lecybyl R, Ociepa M, Loeliger M, Briscoe T, Lambert G, Caddy J, Rehn A, Dieni S, Krozowski Z, Trzeciak WH. Contribution of protein kinase Rees S. Chronic placental insufficiency affects retinal Nestel PJ. Metabolic syndrome; the new cardiovascular A and protein kinase C signalling pathways to the development in the guinea pig. Invest Ophthalmol Vis Sci target. Curr Opin Lipidol 2004;15:1-4. regulation of HSD11B2 expression and proliferation of 2004;45:2361-7. MCF-7 cells. Acta Biochim Pol. 2004;51:919-24. Nigro J, Ballinger ML, Dilley RJ, Jennings GL, Wight TN, Ma G, Allen TJ, Cooper ME, Cao Z. Calcium channel Little PJ. Fenofibrate modifies human vascular smooth Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, blockers, either amlodipine or mibefradil, ameliorate renal muscle proteoglycans and reduces lipoprotein binding. Layfield SL, Mak J, Tregear GW, Du XJ. Relaxin modulates injury in experimental diabetes. Kidney Int Diabetologia 2004;47:2105-13. cardiac fibroblast proliferation, differentiation, and 2004;66:1090-8. collagen production and reverses cardiac fibrosis in vivo. Olchawa B, Kingwell BA, Hoang A, Schneider L, Miyazaki Endocrinology 2004;145:4125-33. MacIsaac RJ, Jerums G, Cooper ME. New insights into the O, Nestel P, Sviridov D. Physical fitness and reverse significance of microalbuminuria. Curr Opin Nephrol cholesterol transport. Arterioscler Thromb Vasc Biol Schlaich M, Lambert E. Hypertensive left ventricular Hypertens 2004;13:89-91. 2004;24:1087-91. hypertrophy. Cardiology Review 2004;21:31-5.

Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Onan D, Hannan RD, Thomas WG. Urotensin II: the old kid Schlaich MP,Ahlers BA, Parnell MM, Kaye DM. beta- Bergin P, Naughton MT. Controlled trial of continuous in town. Trends Endocrinol Metab 2004;15:175-82. Adrenoceptor-mediated, nitric-oxide-dependent positive airway pressure in obstructive sleep apnea and vasodilatation is abnormal in early hypertension: heart failure. Am J Respir Crit Care Med 2004;169:361-6. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin restoration by L-arginine. J Hypertens 2004;22:1917-25. II promotes hypertrophy of cardiac myocytes via mitogen- Mayorov DN, Head GA, De Matteo R. Tempol attenuates activated protein kinases. Mol Endocrinol 2004;18:2344-54. Schlaich MP, Esler MD. Response: Neural Sympathetic excitatory actions of angiotensin II in the rostral Activity in Essential Hypertension. Hypertension ventrolateral medulla during emotional stress. Parfyonova Y, Plekhanova O, Solomatina M, Naumov V, 2004;[Epub ahead of print]. Hypertension 2004;44:101-6. Bobik A, Berk B, TkachukV. Contrasting effects of

www.baker.edu.au 37 Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell with GFR and anemia in patients with type 2 diabetes. Cameron JD, Gatzka CD, Kingwell BA. Large Artery DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Kidney Int 2004;66:1167-72. Function: Measurements, Methods, Mechanisms and Sympathetic augmentation in hypertension: role of nerve Meaning. In: In Vivo Assessment of Vascular Function firing, norepinephrine reuptake, and Angiotensin Thomas WG, Qian H, Smith NJ. When 6 is 9: ‘uncoupled’ in Humans. Nova Science Publishers, Inc. New York, neuromodulation. Hypertension 2004;43:169-75. AT1 receptors turn signalling on its head. Cell Mol Life Sci USA; 2004. 2004;61:2687-94. Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Candido R, Burrell LM, Jandeleit-Dahm K, Cooper ME. Zhang WZ, Kaye DM. Impaired L-arginine transport and Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M. Vasoactive peptides and the kidney. In: Brenner and endothelial function in hypertensive and genetically Connective tissue growth factor is up-regulated in the Rector’s The Kidney, 7th edition. (Chapter 16); 2004. p. predisposed normotensive subjects. Circulation diabetic retina: amelioration by angiotensin-converting 663-726. 2004;110:3280-6. enzyme inhibition. Endocrinology 2004;145:860-6. Esler M. Looking at the sympathetic nervous system as a See F,Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Tikellis C, Johnston C, Forbes J, Burns W, Thomas M, Lew primary source. In: Handbook of Hypertension: Itescu S, Krum H. p38 mitogen-activated protein kinase R, Yarski M, Smith A, Cooper M. Identification of Hypertension Research in the Twentieth Century. Eds. inhibition improves cardiac function and attenuates left angiotensin converting enzyme 2 in the rodent retina. Zanchetti A, Robertson JIS, Birkenhager WH. Elsevier, ventricular remodeling following myocardial infarction in 2004;29:419-27. Amsterdam.; 2004. p. 81-103. the rat. J Am Coll Cardiol 2004;44:1679-89. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Esler M, Alvarenga M, Kaye D, Lambert G, Thompson J, Sher LB, Woitge HW, Adams DJ, Gronowicz GA, Krozowski Thomas MC, Cooper ME. Improved islet morphology after Hastings J, Schwarz R, Morris M, Richards J. Panic Z, Harrison JR, Kream BE. Transgenic expression of blockade of the renin- angiotensin system in the ZDF rat. Disorder. In: Primer of the Autonomic Nervous System. 11beta-hydroxysteroid dehydrogenase type 2 in Diabetes 2004;53:989-97. Eds. Robertson D, Low PA, Burnstock G, Biaggioni I. osteoblasts reveals an anabolic role for endogenous Elsevier, Amsterdam.; 2004. p. 391-394. glucocorticoids in bone. Endocrinology 2004;145:922-9. Twigg SM, Cooper ME. The time has come to target connective tissue growth factor in diabetic complications. Kingwell BA, Jennings GL, Cameron JD. Non- Smith NJ, Chan HW, Osborne JE, Thomas WG, Hannan RD. Diabetologia 2004;47:965-8. pharmacological treatment for increased arterial stiffness Hijacking epidermal growth factor receptors by angiotensin and altered wave reflections. In: Handbook of Hypertension. II: new possibilities for understanding and treating cardiac Vaughan R, Angus P, Chin-Dusting JPF.Author's reply: Ed ME Safar and ME O'Rourke. Elsevier, UK; 2004. hypertrophy. Cell Mol Life Sci 2004;61:2695-703. Responses to endothelian-1 in patients with advanced cirrhosis before and after liver transplantation. Gut Little PJ, Topliss DJ, Mudaliar S, Law RE. Proliferator- Tannock LR, Little PJ, Tsoi C, Barrett PH, Wight TN, Chait. 2004;53:773. Author’s Reply. activated receptors and diabetic vasculature. In: Diabetes Thiazolidinediones reduce the LDL binding affinity of non- and Cardiovascular Disease: Integrating Science and human primate vascular cell proteoglycans. Diabetologia Widlansky ME, Biegelsen ES, Hamburg NM, Duffy SJ, Clinical Medicine.Eds and S. P. Marso and D. M. 2004;47:837-43. Keaney JF Jr, Vita JA. Coronary endothelial dysfunction is Lippincott, Williams and Wilkins Philadelphia USA; 2004. not rapidly reversible with ascorbic acid. Free Radic Biol p. 75-91. Taylor AJ, Bobik A, Berndt MC, Kannelakis P, Jennings G. Med 2004; 36:123-30. Serotonin blockade protects against early microvascular Medley TL, Kingwell BA. Large artery stiffness: Structural constriction following atherosclerotic plaque rupture. Eur J Wigg SJ, Tare M, Forbes J, Cooper ME, Thomas MC, and genetic aspects. In: Progress in Atherosclerosis Pharmacol 2004;486:85-9. Coleman HA, Parkington HC, O'Brien RC. Early vitamin E Research. Ed Frank Columbus. Nova Science Publishers, supplementation attenuates diabetes-associated vascular Inc. New York, USA.; 2004. Taylor AJ, Bobik A, Richards M, Kaye D, Raines G, Gould P, dysfunction and the rise in protein kinase C-beta in Jennings G. Myocardial endothelin-1 release and indices mesenteric artery and ameliorates wall stiffness in femoral Safar ME, Kass D, Asmar R, Kingwell BA. Basis for a de- of inflammation during angioplasty for acute myocardial artery of Wistar rats. Diabetologia 2004;47:1038-46. stiffening strategy of anti-hypertensive drugs. In: infarction and stable coronary artery disease. Am Heart J Handbook of Hypertension. Ed ME Safar and ME 2004;182:e10. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, O’Rourke. Elsevier, UK.; 2004. Funder JW, Sudhir K, Komesaroff PA. Terra SG, Blum RA, Wei GC, Lew RA, Digenio AG, Rajman Dehydroepiandrosterone increases endothelial cell Sviridov D, Nestel P.Assessment of reverse cholesterol I, Kazierad DJ. Evaluation of methods for improving proliferation in vitro and improves endothelial function in transport. In: Trends in Atherosclerosis Research: (LV Clark precision of blood pressure measurements in phase I vivo by mechanisms independent of androgen and estrogen ed), Nova Science Publishers); 2004. p. 257-281. clinical trials. J Clin Pharmacol 2004;44:457-63. receptors. Clin Endocrinol Metab 2004;89:4708-15. Thomas MC, Cooper ME. Diabetic nephropathy. In: The Thomas M, Tikellis C, Kantharidis P, Burns W, Cooper M, Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Year in Renal Medicine. ed. Levy J. Clinical Publishing, Forbes J. The role of advanced glycation in reduced Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro Oxford UK.; 2004. organic cation transport associated with experimental M, Parker JD, Bourassa MG, Dart, AM, Hildebrandt P. Et al. diabetes. J Pharmacol Exp Ther 2004;311:456-66. Effect of long-acting nifedipine on mortality and Thomas MC, Jerums G, Cooper ME. Advanced Glycation cardiovascular morbidity in patients with stable angina End Products in Diabetic Renal Disease. In: The Kidney Thomas MC, Cooper ME. Blockade of the renin- requiring treatment (ACTION trial): randomised controlled and Hypertension in Diabetes Mellitus, 6th edition. In angiotensin system: better late than never. Am J Kidney trial. Lancet 2004;364:849-57. Mogensen CE, Taylor and Francis Publishers (ed) London Dis 2004;43:1113-5. UK; 2004. p. 303-322. Woodcock E. Editorial on: Human cardiac phospholipase Thomas MC, Johnston CI. Valsartan - a drug monograpgh. D activity is tightly controlled by phosphatidylinositol 4,5- Book Reviews J Drug Eval 2004;2:1-35. bisphosphate, T. Kurz, D. Kemken, K. Mier, I. Weber, G. Chellappah J, Chin-Dusting J. Book review: Systematic Richardt. J Mol Cell Cardiol 2004;36:207-11. reviews to support evidence-based medicine (Khan KS) Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Royal Society of Medicine Press Ltd, London, 2003. Goubina I, Fulcher G, Yue D, Jerums G. The burden of Zhang WZ, Kaye DM. Simultaneous determination of Current Medical Research and Opinion; 2004;20:1329. anaemia in type 2 diabetes and the role of nephropathy: arginine and seven metabolites in plasma by reversed- a cross-sectional audit. Nephrol Dial Transplant phase liquid chromatography with a time-controlled Connelly N, Chin-Dusting J. Book review: Key topics in 2004;19:1792-7. ortho-phthaldialdehyde precolumn derivatization. Anal Clinical Research (Gao Smith F, Smith JE) BIOS Scientific Biochem 2004;326:87-92. Publishers Ltd, Oxford, 2003. Current Medical Research Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, and Opinion; 2004;20:127-128. Goubina I, Fulcher G, Yue D, Jerums G. Anemia in patients Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression with type 1 diabetes. J Clin Endocrinol Metab of vascular endothelial growth factor is mediated by Esler MD. Book review: Metabolic syndrome and 2004;89:4359-63. angiotensin type 1 and type 2 receptors. Hypertension hypertension: what are the outstanding problems. Dialog 2004;43:276-81. Cardiovasc Med; 2004;9:167-172. Thomas MC, MacIssac R, Tslamandris C, Jerums G. Abnormal iron indices in patients with diabetes; a cross Book Chapters Huynh N, Chin-Dusting J. Book review: The Field Guide to sectional survey. Diabet Med 2004;21:798-802. Boner G, McNally PJ, Cooper ME. Antihypertensive MEDLINE: Making Searching Simple (Stave CD) Lippincott, treatment in NIDD, with special reference to abnormal Williams and Wilkins, Philadelphia, 2003. Current Medical Thomas MC, Tsalamandris C, MacIsaac R, Medley T, albuminuria. In: The Kidney and Hypertension in Diabetes Research and Opinion; 2004;20:129. Kingwell B, Cooper ME, Jerums G. Low-molecular-weight Mellitus. 6th Edition. CE Morgensen, Taylor and Francis AGEs are associated with GFR and anemia in patients Publishers. London UK; 2004. p. 579-610. advertising mercury

38 sx2188 SUPPORTING THE BAKER

How you can support the Baker

The Baker Heart Research Institute relies on non-government sources, including donations from members of the public for a substantial part of its operating income. The Baker enjoys an international reputation for the high quality of its research into the causes of cardiovascular disease. It is an established centre for training in medical research, providing post-graduate education and on the job training in specialised techniques. You can support our research and help us continue our work in this important area. Use of donated funds

All donations are used to support the Baker’s medical research program, and in particular to assist with attracting talented scientists, the purchase of equipment and maintaining laboratory supplies. We will happily discuss donation options with you, and are pleased to direct donations as requested. ALL DONATIONS OVER $2 ARE TAX DEDUCTIBLE

• Individual Donations • Corporate Support • Becoming a Member of a Baker Club • Scholarship Program

• Memorial Gifts - a gift in lieu of flowers when a loved one passes away

• Gifts for life – celebrate a birthday or anniversary with donations to support the Baker in lieu of gifts

• Volunteering • Holding an event to raise funds for the Baker • A gift in your Will

If you would like any further information on ways to support the Baker please contact us: Telephone: 1300 728 900 Mail: Baker Heart Research Institute PO Box 6492, St Kilda Road Central Melbourne 8008 Or look at the pages on how you can support the Baker online at www.baker.edu.au

39 PO Box 6492, St Kilda Road Central, Melbourne Victoria 8008 Australia Telephone 61 3 8532 1111 Facsimile 61 3 8532 1100 www.baker.edu.au